Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases

Zhenzhen Zhai 1, Yanxin Huang 1, Yawei Zhang 1, Lili Zhao 1 and Wen Li 1,2, *

1 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
2 Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education & Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, China
* Correspondence: liwen@zzu.edu.cn; Tel.: +86-0371-67781908

Abstract: Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, lupus erythematosus, and liver injury.

Keywords: Nrf2; clinical research; small molecule compounds; inflammation-related diseases; COVID-19; Alzheimer’s disease; Parkinson’s disease; lupus erythematosus; liver damage

1. Introduction to Nrf2 Function

Oxidative stress refers to the imbalance between oxidation and antioxidants and is caused by the production of reactive oxygen species (ROS) in the body, resulting in oxidative damage to tissue and cells. The Nrf2/Keap1 pathway is the principal protective response to oxidative and electrophilic stresses. Kelch-like ECH-associated protein 1 (Keap1) is a component of the Cullin 3 (CUL3)-based E3 ubiquitin ligase complex and controls the stability and accumulation of Nrf2 [1–7]. Normally, Nrf2 exists in the cytoplasm under the regulation of Keap1 and maintains low activity in a normal physiological state. When cells are stimulated by oxidative stress, Nrf2 detaches from Keap1 and translocates into the nucleus to form heterodimers with musculoaponeurotic fibrosarcoma (MAF), bind antioxidant response element (ARE), and activate the expression of Nrf2 target genes (Phase II detoxification enzymes and antioxidant enzyme genes), such as heme-oxigenase-1(HMOX-1), NAD (P) H-quinone oxidoreductase 1 (NQO1) and glutamate cysteine ligase (GCL), glutathione S-transferase(GST), superoxide dismutase (SOD), γ-glutamyl cysteine synthetase (γ-GCS), glutathione peroxidase (GSH-Px), γ-glutamyl cysteine synthetase catalytic subunit(GCLC), γ-glutamyl cysteine synthetase modifier subunit(GCLM), etc. [8,9]. The functions of the proteins they encode are as follows: HO-1 is encoded by the HMOX-1 gene, which catalyzes the decomposition of heme with cytochrome P450 to produce biliverdin, etc., and then biliverdin is converted into bilirubin. Both biliverdin and bilirubin have antioxidant and immunomodulatory properties [10]. NQO1 protects cells from the harmful effects of quinone redox cycling [11]. GCL consists of GCLC and GCLM and is the rate-limiting enzyme in the glutathione biosynthetic pathway. GST mainly catalyzes the covalent combination of various chemicals and their metabolites with the sulfhydryl group of glutathione (GSH), making electrophilic compounds into hydrophilic substances, which
are easy to excrete [12,13]. SOD catalytically converts the superoxide radical to hydrogen peroxide (H$_2$O$_2$), constituting the first line of defense against oxidative stress [14]. γ-GCS catalyzes the rate-limiting biosynthesis of GSH, an abundant physiological antioxidant that plays important roles in regulating oxidative stress. GSH-Px specifically catalyzes the reaction of GSH with ROS, thereby protecting cells from ROS damage [15,16]. Nuclear factor kappa B (NF-kB) is closely related to the regulation of inflammation by participating in the activation of genes encoding proinflammatory cytokines, growth factors, and inducible enzymes, such as interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and inducible nitric oxide synthase (iNOS). Nrf2 reduces inflammatory response by inhibiting the activity of NF-kB through the Nrf2-ARE pathway and by directly inhibiting the activity of NF-kB and the expression of proinflammatory cytokine genes (Figure 1) [17]. Numerous studies have shown that Nrf2 and NF-kB play important roles in regulating cancer responses to chemotherapy [18,19] and the immune/inflammatory cancer microenvironment in almost all types of cancer [20].

Figure 1. Mechanisms of Nrf2 signaling pathway regulating inflammation.

2. Research Progress of Nrf2 in Inflammation-Related Diseases
2.1. Nrf2 and Coronavirus Disease 2019 (COVID-19)

COVID-19 is a complex infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical evidence has shown that the main symptoms of COVID-19 can include acute infection of the respiratory tract, as well as inflammatory reactions of multiple organs [21,22]. SARS-CoV-2 enters cells by first binding to angiotensin-converting enzyme 2 (ACE2), followed by cleavage of the virus spike protein by transmembrane protease serine 2 (TMPRSS2) [23]. Nrf2 located in the nucleus can directly inhibit the expression of ACE2 and TMPRSS2 on the cell surface to reduce SARS-CoV-2 entry into cells; it can also block the replication of the viral genome by mediating the
production of type I interferons (IFN-I) by HO-1 [24–26]. Through these two mechanisms, the Nrf2 signaling pathway can effectively reduce SARS-CoV-2 infection (Figure 2).

**Figure 2.** Antiviral effects of Nrf2 pathway on SARS-CoV-2.

At present, seven Nrf2 agonists have entered clinical trials as COVID-19 treatments (Scheme 1 and Table 1). These compounds are discussed below.

Epigallocatechin gallate (EGCG) (1, 50% inhibitory concentration (IC$_{50}$) is 7.51 µM [27]) (3CL Protease (M$_{pro}$) (SARS-CoV-2) Assay Kit [BPS bioscience, https://bpsbioscience.com/ (accessed on 3 August 2022)] using the fluorescence method) is the main component of green tea polyphenols; it is a catechin monomer isolated from tea and is a flavanol compound. EGCG has entered phase 2/3 clinical trials. According to the strength of oxidation, the order of oxidation of EGCG and its three derivatives (Epigalloeatechin) EGC, (Epieatechin gallate) ECG, (Epieatechin) EC) is: EGCG > EGC > ECG > EC [27–35]. Therefore, it can be speculated that the 3',4',5'-trihydroxyl group of the B ring in the EGCG structure is important for its antioxidant capacity. The gallic acid ester of the D ring also contributes to its antioxidant capacity, and studies have shown that the two may be involved in metal chelation. Multiple phenolic hydroxyl groups endow EGCG with robust antioxidant activity, high hydrophilicity, and active properties, so its stability should be fully considered when designing a drug.

Sulforaphane (2, IC$_{50}$ is 2.4 µM ) (quantification of viral RNA from SARS-CoV-2-infected human intestinal Caco-2 cells treated with SFN using qPCR) is produced through the hydrolysis of glucosinolates, which are found in cruciferous vegetables, such as cabbage and radishes [36–43]. Sulforaphane has entered phase 2 clinical trials. The bioavailability of sulforaphane is approximately 80%. However, its disadvantages are its instigation of strong irritation, volatility, and sensitivity to temperature and pH. The isothiocyanate group is the pharmacophore of sulforaphane. Converting methylsulfinyl to an acetyl group or N-methylformamide reduces its antioxidant capacity; however, when converted to squaramide, its antioxidant capacity is 25 times greater than that of sulforaphane [44]. Therefore, it is possible to modify the structure of the butyl carbon chain of sulforaphane to make it less irritating and more stable.

Resveratrol (3, IC$_{50}$ is 0.98 µM [45]) (detection of the inhibitory activity of resveratrol on COX-2 enzymes using a COX-2 inhibitor screening kit using the fluorescence method) is found in plants such as blackberries, peanuts, and grapes and has good anti-inflammatory and anti-SARS-CoV-2 activities as an Nrf2 agonist [45–49]; this compound has entered phase 3 clinical trials. The resveratrol–ibuprofen combination, in which the hydroxyl group on the B ring is monosubstituted, has a more significant anti-inflammatory effect than either compound.
given alone [50]. Pei Ling et al. once discussed the relationship between antioxidation and chemical structure of resveratrol and its analogues (Scheme 1) and put forward the concept of hydrogen-donating ability. Using quantum chemical calculations based on the density functional theory (DFT), they calculated the hydrogen-donating ability of these compounds. The order of these compounds is C > D > B > G > E > A > F, and the antioxidation of these compounds is positively correlated with their hydrogen-donating ability [51].

![Scheme 1. Structures and numbers of seven Nrf2 agonists promising for the treatment of COVID-19.](image)

Dimethyl fumarate (DMF) (4, $IC_{50}$ is 9.30 µM [52]) (detection of the inhibitory activity of DMF on IL-6 produced by lipopolysaccharide-induced dTHP-1 cell line using IL-6 commercial kits (Perkin Elmer) and the fluorescence method) is a US Food and Drug Administration (FDA)-approved synthetic drug used as an anti-inflammatory therapeutic for multiple sclerosis (MS) via Nrf2 inhibition of pathogenic inflammation [53,54], and it is currently in phase 2/3 clinical trials. Isosorbide di-(methyl fumarate) (IDMF), with a central isosorbide moiety and two methyl fumarate groups, can partially replicate DMF activity and is nonirritating and nonsensitizing when applied to the skin [55]. When the carboxyl groups at both ends of the DMF structure were changed to 4-chlorophenyl ester, Ar-NH-, and Ar-CH2-NH-, anti-inflammatory efficacy was greatly improved [56]. Based on the above, we preliminarily hypothesize that the intermediate chain ketone-ene-ketone structure of DMF may be an essential group for its activity and that the carboxyl groups at both ends can be transformed to synergistically improve the detoxification of the compound.
Table 1. Seven Nrf2 agonists used in some clinical trials for COVID-19.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| **BECC (D)** | Proviren® as Chemoprophylaxis of COVID-19 in Health Workers | 2/3 | Unknown | Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rRT-PCR | 250 mg/3 h orally for 40-70 days | Sample size: 524; Gender: all; Ages: 25 years and older | NCT04446055 |
| **Sulforaphane (D)** | COX-2 Inhibitor Broccoli sprout powder for COVID-19 positive pregnant women on the rate of hospital admission | 2 | Australia | Duration of COVID-19 associated symptoms (days) as self-reported by trial participants | 21 mg, orally twice a day, morning and night (BID) | Sample size: 60; Gender: females; Ages: 18 years and older | ACTRN12620001377996 |
| | SEPSIS treatment for Acute Respiratory Infections (STAR-Covid19) | 2 | Australia | 1. Not hospitalized, no limitations on activities. 2. Not hospitalized, limitation on activities. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, requiring supplemental oxygen. 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices. 6. Hospitalized, on invasive mechanical ventilation or ECMO (Extracorporeal membrane oxygenation). 7. Death (impropriety) or evaluation of this end point day 15 (where day 1 is the first day of treatment). | 300 mg, orally | Sample size: 500; Gender: all; Ages: adults (18-64 years): 120; elderly (>65 years): 180 | NCT03961836 |
| | The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients | N/A | Hong Kong, China | Clinical symptoms duration. Time Frame: 1 month, starting after start of treatment. | 1.5 g, orally once a day for six months. | Sample size: 50; Gender: all; Ages: 18 years to 99 years | NCT04799743 |
| | Retrospective Study of ImmunoFormulation for COVID-19 | N/A | Spain | 1. The handheld basic spirometry; 2. PRO scores; 3. Borg Category Rate (0-10 Scale). | transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at <10 kDa—Imuaca 1™); 300 mg, 800 mg anti-inflammatory natural blend (Aliciae tomentosa, Endophasia uchi and Haematoxylum ptilipedum—MoosMegTM), 50 mg zince citrate, 45 mg selenium yeast (equivalent to 96 µg of Se), 20(05 IU cholecalciferol), 300 mg aceric acid, 400 mg female acid, 90 mg resveratrol, 500 mg aliciun, 500 mg N-acetylcysteine, 30 mg glucosamine-phosphate potassium chloride, and 400 mg multimineral-multivitamin orthosilicate acid (equivalent to 4 mg of 5%—SilinaMax®). | Sample size: 50; Gender: all; Ages: 18 years to 99 years | NCT0446783 |
| | Evaluation of the combined effect of Hesperidin, Artemisia artemis annua, N-acetylcyctine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19 | 3 | Iran (Islamic Republic of) | LIDH, CBC def, Na/K/Ca, CRP, ESR, Wnkness and nausea, respiratory quality. | S.²—SilinaMax® | Sample size: 100; Gender: all; Ages: 12 years and older. | IRCT20181010041504N1 |
| | Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy | N/A | United States | 1. Reduction in SARS-CoV-2 viral load; 2. Reduction in severity of COVID-19 Disease. | Zinc Picrolinate (50 mg po TID = 5 days); neoversatrol (2 g po BID = 5 days) | Sample size: 45; Gender: all; Ages: 18 years to 77 years | NCT04542983 |
| **Resveratrol (D)** | Randomized Controlled Trial of Resveratrol-Copper Or Sodium-Copper-Chlorophyllin Versus Standard Treatment in Severe COVID-19 Patients | 2 | India | The time to clinical improvement, defined as a two-point improvement on a seven-point ordinal scale. | Tablet of neoversatrol-Cu containing 5.6 mg of resveratrol and 560 ng of copper, orally once every 6 h. | Sample size: 200; Gender: all; Ages: 18 years to 99 years | CTRI/2020/07/026514 |
| | Randomized Controlled Trial of Resveratrol-Copper Or Sodium-Copper-Chlorophyllin Versus Standard Treatment in Mild COVID-19 infection with Cancer Patients | 3 | India | The proportion of patients who suffer clinical deterioration OR viral persistence at Day 10 from the date of randomization (excluding the date of randomization). | Tablet of neoversatrol-Cu containing 5.6 mg of resveratrol and 560 ng of copper, orally once every 6 h. | Sample size: 200; Gender: all; Ages: 18 years to 99 years | CTRI/2020/07/026515 |
| | Resveratrol and copper for the treatment of COVID-19 pneumonia | N/A | India | To retrospectively access the clinical outcomes in the patients receiving KCu along with standard treatment versus those who received standard treatment. | Tablet of neoversatrol-Cu containing 5.6 mg of resveratrol and 560 ng of copper, orally once every 6 h. | Sample size: 200; Gender: all; Ages: 18 years to 99 years | CTRI/2020/07/026514 |
| | Resveratrol in COVID-19 | 3 | Iran (Islamic Republic of) | 1. Time to clinical recovery; 2. Respiratory signs; 3. Intubation rate | 500 mg, orally once a day for 14 days | Sample size: 250; Gender: all; Ages: 18 years to 99 years | IRCT20200112046089N1 |
| | Randomized Controlled Trial of Resveratrol-Copper Or Sodium-Copper-Chlorophyllin Versus Standard Treatment in COVID-19 infection | 3 | India | Proportion of patients who suffer clinical deterioration OR viral infection; 2. Persistence at day 10 from the date of randomization (excluding the date of randomization). | Tablet of neoversatrol-Cu containing 5.6 mg of resveratrol and 560 ng of copper, orally once every 6 h. | Sample size: 300; Gender: all; Ages: 18 years to 99 years | CTRI/2020/05/025526 |
| | Randomized Controlled Trial of Resveratrol-Copper Or Sodium-Copper-Chlorophyllin Versus Standard Treatment Severe COVID-19 | 2 | India | The time to clinical improvement, defined as a two-point improvement on a seven-point ordinal scale. | Tablet of neoversatrol-Cu containing 5.6 mg of resveratrol and 560 ng of copper, orally once every 6 h. | Sample size: 200; Gender: all; Ages: 18 years to 99 years | CTRI/2020/05/025537 |
### Table 1. Cont.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| Antioxidants | Fumarate | 3 | Iran (Islamic Republic of) | Clinical symptoms changes (dry cough, respiratory distress, fever) | 240 mg capsules (CienaGen, Tehran, Iran) daily for 5-7 days | Sample size: 30; Gender: all; Ages: 18 years and older | NCT04193167 |
|              |        | 2 | United States | Hospitalization rate for COVID-19 proportion of study participants admitted to the hospital within 21 days of randomization | 120 mg every 12 h or 4 doses followed by 240 mg every 12 h by mouth for 8 days (30 days in total) | Sample size: 30,000; Gender: all; Ages: child, adult and older adult | NCT08004980 |
| Resorveratrol | (Q) | 2 (Termini- | United States | “Curcumin and Resorveratrol” capsule (each capsule contains 200 mg of curcumin, 200 mg of resorveratrol as active ingredients and 300 mg of lactose as filler), 1 capsule every 12 h for 7 days | Sample size: 60; Gender: all; Ages: 18 years and older | |
|              |        | rated)  |             | Resorveratol 180 mg 4 times/day for 15 days. Vitamin D5 100,000 IU on day 1 | Resorveratol 180 mg 4 times/day for 15 days. Vitamin D5 100,000 IU on day 1 | |
| Dimethyl | Fumarate | 2/3 | Iran (Islamic Republic of) | Death; need for mechanical ventilation; severe illness. | Sample size: 100; Gender: all; Ages: 45 years and older | |
| Treatment |       | 2/3 | United Kingdom; Nepal; Sri Lanka; China; Vietnam; Indonesia; India; South Africa | All-cause mortality: For each pairwise comparison with the "no additional treatments" arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality. | |
| The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients with Post-acute COVID-19 Syndrome | Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19 | N/A | Unknown | Change in health-related quality of life is measured with the "Short-Form 12" (SF-12) from 0 to 100. | Sample size: 52; Gender: all; Ages: 18 years to 85 years | |
|              |       | N/A | Pakistan | 1. Testing negative for SARS-CoV-2 using RT-PCR; 2. COVID-19 symptom improvement | Sample size: 50; Gender: all; Ages: 18 years and older | |
|              |       | 3 | India (Islamic Republic of) | Clinical symptoms, radiological findings, laboratory findings. | Sample size: 200; Gender: all; Ages: 18 years and older | |
| Determining the Safety and Effectiveness of ENDOR Oral Combination Drug in the Treatment of Patients with COVID-19 | Nanocurcumin (6C & 30C) on incidence of ILI & COVID-19 type respiratory illness | 3 | India | Incidence of influenza-like illness and COVID-19 type respiratory illness. | Sample size: 7,000; Gender: all; Ages: 1 year and over | CTRI202106051006626 |
| Effect of Bromelain, Curcumin and Epigallocatechin in the treatment of outpatient COVID-19 patients | Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 | 2 | Israel | Blood oxygen saturation, sense of smell, sense of taste, fever, lung involvement, cough, muscle pain, weakness, gastrointestinal symptoms, death, hospitalization. | Sample size: 300; Gender: all; Ages: 18 years and older | |
| Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 | Effect of Bromelain, Curcumin and Epigallocatechin in the treatment of outpatient COVID-19 patients | 3 | Israel | Clinical improvement in treatment groups. Time frame: up to 28 days. | Sample size: 240; Gender: all; Ages: 18 years and older | |
| Curcumin (Q) | A clinical study to see the effect of ArtemiC in patients with COVID-19 | N/A | India | Blood oxygen saturation, sense of smell, sense of taste, fever, lung involvement, cough, muscle pain, weakness, gastrointestinal symptoms, death, hospitalization. | Sample size: 252; Gender: all; Ages: 18 years and over | |
| Oral Curcumin, Quercetin and Vitamin-D3 Supplements for Mild to Moderate Symptoms of COVID-19 | Assessment of the effect of nanocurcumin supplement in patients with COVID-19 | N/A | Pakistan | In-CRP, recovery percentage, percentage of oxygen saturation, severity of infection symptoms of upper and lower respiratory tract, CRP. | Sample size: 46; Gender: all; Ages: 30 years to 70 years old | |
| Effect of curcumin in treatment of respiratory syndrome of patients | Effect of curcumin in treatment of respiratory syndrome of patients | 2/3 | Iran (Islamic Republic of) | Body temperature, oxygen saturation, chest X-ray scan at the beginning of the study and on the third and seventh days. | Sample size: 42; Gender: all; Ages: no age limit | |
| Evaluation of the effect of curcumin in improving patients with COVID-19 | Curcumin for COVID-19 Pre Exposure Prophylaxis | Evaluation of the effect of curcumin in improving patients with COVID-19 | Iran (Islamic Republic of) | Immunologic and radiologic findings; hospitalization duration; CRP, LDH, CRP, PT, TT, D-DIMER, BUN, CR. | Sample size: 60; Gender: all; Ages: 18 years to 70 years old | |
| A clinical study to see the effect of ArtemiC in patients with COVID-19 | Effect of Bromelain, Curcumin and Epigallocatechin in the treatment of outpatient COVID-19 patients | 4 | India | SARS-CoV-2 infection rate Using RT-PCR. Time Frame: up to 12 weeks. | Sample size: 200; Gender: all; Ages: 18 years to 65 years | |
| Curcumin for COVID-19 Pre Exposure Prophylaxis | Effect of curcumin in treatment of respiratory syndrome of patients | 2 | Iran (Islamic Republic of) | Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of 2 maintained for 24 h in comparison to routine treatment (measured on days 7, 14, 28) | Sample size: 100; Gender: all; Ages: 18 years and older | |
| A clinical study to see the effect of ArtemiC in patients with COVID-19 | Evaluation of the effect of nanom particles containing curcumin (Sina Curcumin) as a therapeutic supplement in patients with COVID-19 | N/A | Iran (Islamic Republic of) | Clinical improvement in treatment groups. Time frame: up to 28 days. | Sample size: 50,000; Gender: all; Ages: child, adult and older adult | |
| Oral curcumin capsule 500 mg twice daily (morning, evening) for 12 weeks. | ArtemiC containing 12 mg artemisinin, 40 mg curcumin, 30 mg and Vitamin C 120 mg. ArtemiC-A containing a combination of Curcumin 28 mg, Boswellia 21 mg and vitamin C 84 mg. Spray administration twice a day on days 1 and 2. | CTRI20210204357161 |
| 80 mg nanocurcumin orally once every 12 h for 6 days. | ArtemiC containing 12 mg artemisinin, 40 mg curcumin, 30 mg frankincense 120 mg and vitamin C as a maximum dose per 24 h, nasal spray, twice a day | Sample size: 50, Gender: all; Ages: 18 years and older | |
| 150 mg curcumin orally every 8 h for 7 days. | ArtemiC containing a combination of artemisin 12 mg, Boswellia 30 mg and Vitamin C 120 mg. ArtemiC-A containing a combination of ArtemiC 8.4 mg, curcumin 28 mg, Boswellia 21 mg and vitamin C 84 mg. Spray administration twice a day on days 1 and 2. | |
| Patients are given 5 curcumin capsules (500 mg) daily after three meals. | Spray administration twice a day on days 1 and 2. | Sample size: 20; Gender: all; Ages: 18 years to 65 years | |
| Oral curcumin capsule 500 mg twice daily (morning, evening) for 12 weeks. | ArtemiC containing 12 mg artemisinin, 40 mg curcumin, 30 mg frankincense 120 mg and vitamin C (60 mg/mL) and oral curcumin capsule 500 mg twice daily (morning, evening) for 12 weeks. | CTRI20210315352360 |
| 166 mg curcumin, 280 mg quercetin, and 380 IU of vitamin D3 orally once a day for 14 days. | Sample size: 50; Gender: all; Ages: 18 years and older | |
| 150 mg curcumin orally every 8 h for 7 days. | Spray administration twice a day on days 1 and 2. Each dose contain 1 mL (10 puffs/pushes on the spray bottle), total daily dose 2 mL (20 puffs/pushes on the spray bottle). The total treatment is 40 puffs over two days. | CTRI20210310267929 |
| 120 mg every 12 h or 4 doses followed by 240 mg every 12 h by mouth for 8 days (30 days in total). | Sample size: 30; Gender: all; Ages: 18 years and older | |
| 80 mg nanocurcumin orally once every 12 h for 6 days. | Sample size: 30,000; Gender: all; Ages: child, adult and older adult | |
| 150 mg curcumin orally every 8 h for 7 days. | Sample size: 60; Gender: all; Ages: 18 years to 70 years old | |
| Oral curcumin capsule 900 mg twice daily (morning, evening) for 12 weeks. | Sample size: 200; Gender: all; Ages: 18 years to 65 years | |
| 166 mg curcumin, 280 mg quercetin, and 380 IU of vitamin D3 orally once a day for 14 days. | Sample size: 60; Gender: all; Ages: 18 years to 70 years old | |
| 80 mg nanocurcumin orally once every 12 h for 6 days. | Sample size: 30,000; Gender: all; Ages: child, adult and older adult | |
| 120 mg every 12 h or 4 doses followed by 240 mg every 12 h by mouth for 8 days (30 days in total). | Sample size: 50,000; Gender: all; Ages: child, adult and older adult | |
| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|-------------|-------|-------|---------------|-------------------|------|----------|--------------------|
| **Curcumin (5)** | Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19 | 3 | Iran (Islamic Republic of) | Cytokine gene expression, cytokine serum levels, clinical symptoms, laboratory findings | 240 mg nanocurcumin for 7 days at the same time with common therapeutic protocol category | 60; Gender: all; Ages: 18 years to 65 years old | IRCT20200510047510N1 |
| | Evaluation efficacy of Curcumin and Resveratrol capsule in controlling symptoms in patients with COVID-19 | 3 | Iran (Islamic Republic of) | Clinical symptoms changes (dry cough, respiratory distress, fever) | Each capsule contains 200 mg of curcumin, 200 mg of resveratrol as active ingredients, 1 capsule every 12 h for 7 days | 60; Gender: all; Ages: 18 years and over | IRCT20080901001165N56 |
| | Effect of curcumin-piperine in patients with coronavirus (COVID-19) | N/A | Iran (Islamic Republic of) | CT of the chest, body temperature, length of hospital stay, hs-CRP, ESR, ALT, AST, LDH, RBC, creatinine, CRP, blood oxidative stress indices (SOD, MDA, TAC), Albumin, Severity of the disease, severity and number of coughs | Two curcumin-piperine capsules (500 mg curcumin + 5 mg piperine) will be given daily for 2 weeks after lunch and dinner. | 100; Gender: all; Ages: 20 years to 75 years old | IRCT2021210310170N46 |
| | Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad | 3 | Iran (Islamic Republic of) | Rates of treatment response and adverse drug reactions | Nanocurcumin capsule 40 mg, two capsules twice daily for 2 weeks, than one capsule twice daily for 2 weeks | 60; Gender: all; Ages: 18 years to 65 years old | IRCT2020040904609N1 |
| | Effects of nano curcumin supplementation on the reduction of inflammation and mortality in patients with coronavirus 2019 admitted to ICU ward of Imam Reza hospital in Tabriz | 2/3 | Iran (Islamic Republic of) | Gene expression rate; cytokine secretion rate; clinical observations; laboratory observations. | Oral 240 mg of nanocurcumin in 3 capsules of 80 mg daily. | 60; Gender: all; Ages: 18 years to 80 years old | IRCT2020052040695N1 |
| **Fluoxetine (6)** | Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression in Papua New Guinea | 2/3 | Papua New Guinea | COVID-19 disease progression (time frame: up to 14 days), SARS-CoV-2 viral load (time frame: up to 7 days) | Fluoxetine 20 mg oral tablets daily for 9 days. Prednisolone 20 mg oral tablets daily for 4 days. Ivermectin 5 mg oral tablets daily for 5 days | 954; Gender: all; Ages: 18 years to 99 years old | NCT05283954 |
| | Fluoxetine to Reduce Hospitalization From COVID-19 Infection (Flu-COVID-19) | 3 | United States | Blood oxygen saturation; number of days of hospitalization; need for intubation; ICU admission; death. | Oral fluoxetine capsules for 28 days, with 10 mg for the first 4 days followed by 20 mg for the rest of the 4-week period. | 72; Gender: all; Ages: 18 years to 65 years old | NCT02090486N1 |
| | Fluoxetine to Reduce Intubation and Death After COVID19 Infection | 4 | United States | Rate of hospitalization; physical symptoms assessed through daily checklist, time frame: 8 weeks | Orally daily following: week 1: one pill (20 mg), week 2: two pills (40 mg), weeks 3-6: three pills (60 mg), week 7: two pills (40 mg), week 8: one pill (20 mg) | 41; Gender: all; Ages: 18 years and older | NCT04570449 |
| **Bardoxolone Methyl (7)** | BARDONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) | 2 | United States | Number of serious adverse events. Time frame: 29 days. | Oral 20 mg once a day for the duration of hospitalization (until recovery) with a maximum treatment duration of 29 days. | 40; Gender: all; Ages: 18 years and older | NCT04494446 |
Curcumin (IC\textsubscript{50} is 20 \mu M [57]) (Researchers pulsed bone-marrow-derived dendritic cells (BMDCs) for 1 h with curcumin before stimulation with the TLR7 ligand R837 followed by ATP to investigate IL-1\beta production.) is a diketone compound extracted from the rhizomes of plants in the Zingiberaceae and Araceae families [54,58,59]. It is in phase 4 clinical trials. The unsaturated carbon chain and hydroxyl group on the benzene ring of curcumin are extremely important for its anti-inflammatory activity. The alkoxy group next to the phenol group and the benzene ring substituted by the strong electron withdrawing group of the ortho-diphenol hydroxyl group can increase its anti-inflammatory ability [60,61]. The hydrophobicity and rapid metabolism of curcumin lead to poor bioavailability. Some studies have structurally modified the phenolic hydroxyl groups at both ends to transform them into ether, which effectively slowed the metabolism of the compound [62].

Fluoxetine (IC\textsubscript{50} is 10 \mu M [63]) (Different concentrations of fluoxetine were added to Vero E\textsubscript{6} cell cultures along with SARS-CoV-2, and the levels of infectious particles in culture supernatants were detected by incubation.) is a synthetic drug that was first approved in Belgium in 1986 for the treatment of depression. It is one of the few classic clinical drugs with Nrf2 agonistic effects [63–66]. It has entered phase 3 clinical trials. There is almost no anti-inflammatory activity when the methylamino group in fluoxetine is replaced by pyrrolidine, imidazole or piperidine, but there is equivalent activity when replaced by morpholine, piperazine, or N-methylpiperazine [67]. In the case of removing the trifluoromethyl benzene ring and replacing the methylamino group with morpholine, there is no anti-inflammatory activity when the ether bond is replaced by a hydroxyl group and an oxime group; when it is replaced by a ketone group, the activity is comparable to that of fluoxetine. There is increased anti-inflammatory activity after the introduction of trifluoromethyl to the carbon [68]. Therefore, it can be speculated that fluoxetine, methylamino groups, trifluoro-methylbenzene rings, and ether linkage are the key groups that affect the activity of fluoxetine analogues.

Bardoxolone methyl (IC\textsubscript{50} is 5.81 \mu M [69]) (detection of the inhibitory activity of Bardoxolone methyl on SARS-CoV-2 3CL\textsubscript{pro} with Thr-Ser-Ala-Val Leu-Gln-pNA-substrate by using absorbance at 390 nm) is a semisynthetic pentacyclic triterpenoid derived from oleanolic acid [69–71]. It has entered phase 2 clinical trials. Suqing Zheng et al. synthesized a series of monocyclic cyanoketene compounds and tested their anti-inflammatory ability. The study showed that the pharmacophore in semisynthetic pentacyclic triterpenoids is not pentacyclic triterpenoid and has nonenolized cyanoketenes rather than a tricyclic skeleton [72]. It is speculated that the A-rings are necessary for the anti-inflammatory activity of bardoxolone methyl. They function as Michael receptors, and the single-ring structure is more potent than the penta-ring structure. One study showed that removal of C-24 at the C-4 position of the A ring led to higher biological activity and that transforming methyl 28-carboxylate into ethylamide or trifluoroethylamide improved drug delivery to the brain [73,74]. Thus, the structural modification of C-28 is expected to alter its pharmacokinetic properties.

2.2. Nrf2 and Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology and affects approximately 0.5–1.0% of the world’s population. It often presents with joint involvement, synovitis, and intra-articular cartilage damage [75,76]. It is thought that the etiology of RA is closely related to one’s living environment, genetics, immunity, and other factors. Individuals with genetic factors are affected by their living environment, stress, and other factors, which induce abnormal responses in the innate and adaptive immune systems, leading to the destruction of immune tolerance and thus stimulating an inflammatory response [77,78]. The main pathological feature of RA is inflammation leading to articular cartilage damage caused by cartilage degradation. Many studies have shown that Nrf2 activation is a promising method for the treatment of RA [79]. The Kelch-Nrf2/ARE signal transduction pathway can have beneficial anti-inflammatory and antioxidant effects and can regulate oxidative stress in RA. At its core, increased Nrf2...
activity can regulate mitochondrial function and limit the production of mitochondrial ROS after activation of this pathway [80] (Figure 3).

**Figure 3.** Mechanism of Keap1-Nrf2/ARE signaling pathway in RA.

At present, two Nrf2 agonists have entered clinical research for rheumatoid arthritis (Scheme 1 and Table 2).

First, research has shown that 10 µM (4) significantly inhibits the formation and activity of osteoclasts, and the excessive formation of osteoclasts is related to the bone destruction pathology seen in RA [81–86]. Compound (4) has entered phase 2 clinical trials. Second, 50 µM (5) significantly inhibited the activity of collagen-induced arthritis (CIA) in mouse cells and the expression of proinflammatory factors. These results point to the anti-RA effect [87–92] of (5), which has entered phase 1 clinical trials.

2.3. Nrf2 and Alzheimer’s Disease

Senile plaques formed through the accumulation of β-amyloid(Aβ) and neurofibrillary tangles caused by hyperphosphorylation of tau protein are important pathological features of AD [93]. AD affects more than 50 million people. There are various pathogenic hypotheses of AD, such as the cholinergic hypothesis, the Aβ toxicity hypothesis, the tau protein hypothesis, and the inflammation hypothesis, but the pathogenesis of AD still must be elucidated [94]. A recent experiment showed that *Chlamydia pneumoniae* infection is closely related to AD pathogenesis. *Chlamydia pneumoniae* was shown to enter the nasal cavity of mice and rapidly infect the olfactory and trigeminal nerves, which connect to the brain through the olfactory bulb and brain stem, respectively. Microglia and astrocytes (macrophages of the central nervous system (CNS)) can respond to and engulf bacteria. However, *Chlamydia pneumoniae* can evade destruction by phagocytes and infect glial cells by forming inclusion bodies in these cells. Following infection, activated microglia and astrocytes secrete proinflammatory cytokines, including IL-1β, TNFα, and IL-6, which are neurotoxic and directly increase Aβ production by activating β-site amyloid-precursor-cleaving enzyme (BACE). On one hand, activated microglia reduce the accumulation of Aβ in the brain by increasing their phagocytosis, clearance, and degradation. On the other hand, the continuous activation of microglia caused by their binding to Aβ can increase the production of inflammatory mediators, which further amplifies the neuroinflammatory response, leading to chronic inflammation and AD [95–98] (Figure 4).
Table 2. Two Nrf2 agonists used in some clinical trials for RA.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|-------------------|
| Dimethyl Fumarate (4) | Efficacy and Safety Study of BG00012 with Methotrexate in Patients With Active Rheumatoid Arthritis | 2 | Australia | The primary objective is the proportion of subjects with ACR20 response in their RA at Week 12. | 480 mg/day, oral and 720 mg/day, oral | Sample size: 153; Gender: all; Ages: 18 Years to 75 Years | NCT00810836 |
| Curcumin Longa L in Rheumatoid Arthritis | 1; terminated (insufficient enrollment) | United States | Number of participants with adverse events as a measure of safety and tolerability. | 4 250 mg curcumin capsules twice a day for one month | Sample size: 3; Gender: all; Ages: 18 Years and older. | NCT02543931 |
| Curcumin in Rheumatoid Arthritis | Early phase 1 | United States | American College of Rheumatology 20%. Time frame: 4-month period. | 4 capsules once a day for 2 weeks, and then the dose will be increased to 4 capsules twice a day beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks | Sample size: 40; Gender: all; Ages: 18 Years to 75 Years. | NCT00752154 |
In animal models of AD, Nrf2 inhibits its expression by binding to AREs in the BACE promoter and inhibits Aβ production. It can also induce nuclear dot protein 52 (NDP52) by binding to AREs in the NDP52 promoter, thereby reducing p-tau levels in AD [99–101]. Therefore, the activation of Nrf2 by drug intervention may play a positive role in treating AD patients.

Currently, four Nrf2 agonists have entered clinical research related to AD treatment (Scheme 1 and Table 3). Compound (1) reduces the production of Aβ through the Nrf2 pathway and directly binds to Aβ monomers and dimers, leading to structural remodeling of Aβ and reducing its toxicity [102–107]. This compound has entered phase 2/3 clinical trials. Compound (2) effectively inhibits the production of inflammatory mediators in microglia and improves memory deficits [108–111]. The clinical trial status of (2) has not yet been announced. Compound (3) can reduce neuronal oxidative damage [112,113] and has entered phase 3 clinical trials. Compound (5) reduces Aβ-induced cell death and oxidative stress and significantly improves spatial memory deficits in AD mice [114–116] and has entered phase 2 clinical trials.

2.4. Nrf2 and Parkinson’s Disease

Parkinson’s disease (PD) is a chronic progressive nervous system disease. In late-stage PD, extreme tremors, motor retardation, muscle stiffness, and loss of balance occur [117]. In sporadic and familial PD, α-synuclein(α-syn) aggregates into Lewy bodies and Lewy neurites, which are cytotoxic to dopaminergic neurons and can lead to mitosis and enhance mitochondrial autophagy [118]. The increase in dopamine may affect mitochondrial function, increase ROS levels, affect Nrf2 activity, alter the response to antioxidant damage [119–121], and promote the progressive production and accumulation of Aβ [122]. These effects lead to dysregulated cellular function. However, Nrf2 activation can neutralize ROS, inhibit inflammatory processes, and restore cellular redox balance [123–127]. In PD, there are decreased protein expression levels of phosphatase and tensin homolog (PTEN)-induced kinase (PINK) and Parkin protein; the decreases in these proteins affect mitochondrial function, induce depolarization and fragmentation and reduce adenosine triphosphate (ATP) concentrations (Figure 5) [128]. These changes will affect synaptic function, leading to neurodegeneration and cognitive impairment [124–127]. The Nrf2 upregulation induced by antioxidant therapy was shown to enhance thioredoxin-1 (Trx-1), inhibit the formation of nucleotide-binding domain leucine-rich repeat-related (NLR) family pyrin domain-containing 3 (NLRP3) inflammatory bodies and improve neuronal apoptosis in amyloid precursor protein plus presenilin-1 (APP/PS1) mice [129]. Although some mechanisms are not fully understood, Nrf2 can be considered a useful therapeutic target for PD [130].
Table 3. Four Nrf2 agonists used in some clinical trials for AD.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| EGCG (1)     | Prevention of Cognitive Decline in ApoE4 Carriers with Subjective Cognitive Decline After EGCG and a Multimodal Intervention | N/A | Spain | Preclinical Alzheimer Cognitive Composite Plus exe-like score (ADCS-PACC-like). | Oral 532 mg/day (weight > 50 kg). Oral 266 mg/day (weight < 50 kg). months 1–3: 200 mg/day (200-0-0 mg); months 4–6: 400 mg/day (200-0-200 mg); months 7–9: 600 mg/day (400-0-200 mg); months 10–18: 800 mg/day (400-0-400 mg) | Sample size: 200; Gender: all; Ages: 60 years to 80 years old. | NCT03978052 |
| Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer’s Disease | 2/3 | Germany | ADAS-COG (Score 0–70) (baseline to treatment). Time frame: 18 months. | | | |
| Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer’s Disease—SUN-AK | 2 | Germany | Sample size: 50; Gender: all; Ages: 18 years and older. | | | EUCTR2009-009656-20-DE |
| Sulforaphane (2) | Effects of Sulforaphane in Patients with Prodromal to Mild Alzheimer’s Disease | N/A | China | The Alzheimer’s Disease Assessment Scale. | Oral 2550 mg once a day for 24 weeks. | Sample size: 160; Gender: all; Ages: 50 years to 75 years old. | NCT04213391 |
| BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) | 1 | United States | Assessment of AEs and SAEs. Brain penetration of BDPP. Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia. Memory, executive function, and attention measures (composite). | N/A | Sample size: 14; Gender: all; Ages: 50 years to 90 years old. | NCT02502253 |
| Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer’s Disease | 1 | United States | Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score. | N/A | Sample size: 12; Gender: all; Ages: 60 years to 85 years old. | NCT01716637 |
| Resveratrol (3) | Resveratrol for Alzheimer’s Disease | 2 | United States | Number of adverse events. Change from baseline in volumetric magnetic resonance imaging (MRI). | Begin at 500 mg taken once daily and increase after 13 weeks to 1 g taken by mouth twice daily. | Sample size: 119; Gender: all; Ages: 50 years and older. | NCT01504854 |
| Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer’s Disease | 3; withdrawn (PI has left institution) | United States | Cognition. Time frame: 52 weeks. | Oral 215 mg once a day for 52 weeks. | Sample size: 0. | NCT00743743 |
| Randomized Trial of a Nutritional Supplement in Alzheimer’s Disease | 3 | United States | Alzheimer Disease Assessment Scale (ADAS cog). Time frame: one year. | N/A | Sample size: 27; Gender: all; Ages: 50 years to 90 years old. | NCT00678431 |
| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|-------------------|
| KARVIAH_XTND: Longitudinal follow-up study examining the health and wellbeing of participants for identifying new biomarkers and the impact of lifestyle. (Following a 12 month intervention of curcumin for the prevention of Alzheimer’s disease.) | N/A | Australia | Blood biomarker compared with the brain amyloid levels. Blood biomarkers and PET imaging results. | N/A | Sample size: 100; Gender: all; Ages: 65 years and older. | ACTRN12620001325998 |
| Curcumin and Yoga Therapy for Those at Risk for Alzheimer’s Disease | 2 | United States | Curcumin effects (first six-month period) or curcumin and aerobic yoga effects (second six-month period) on the changes in the levels of blood biomarkers for mild cognitive impairment relative to baseline or relative to placebo or non-aerobic yoga. | Oral 800 mg curcumin in 4 capsules BID per day prior to meals. | Sample size: 80; Gender: all; Ages: 50 years to 90 years old. | NCT01811381 |
| KARVIAH Sub-study: Examining the use of curcumin on cognition and mood in an older population | 2 | Australia | Attention tasks and working memory as measured using a computerized cognitive battery (CogState). | Oral 500 mg 3 times daily. | Sample size: 40; Gender: all; Ages: 65 years to 90 years old. | ACTRN12616001113448 |
| Effect of curcumin (tumeric) in Alzheimer’s disease | N/A | Iran (Islamic Republic of) | MMSE and quality of life questionnaires. Time frame: before and after intervention (12 weeks). | Oral 500 mg twice a day for 12 weeks. | Sample size: 70; Gender: all; Ages: no age limit. | IRCT201507271165N11 |
| The epigenetic effect of curcumin as measured in the blood and seen within lifestyle, for the prevention of Alzheimer’s disease | 2 | Australia | Measurement of blood biomarkers within healthy and MCI groups. | Oral 1.5 mg daily (×3 divided doses) for a period of 3 or 6 months. | Sample size: 60; Gender: all; Ages: 65 years to 90 years old. | ACTRN12614001024639 |
| McCusker KARVIAH: Curcumin in Alzheimer’s disease prevention | 2 | Australia | AD-related blood biomarker profiles. Pib PET imaging. Neuropsychological tests. Time frame: up to 12 months. | 500 mg daily for 2 weeks, progressing to 500 mg twice daily (1000 mg/daily) for 2 weeks, then 500 mg three times daily (1500 mg) for a period of 12 months in total. | Sample size: 134; Gender: all; Ages: 65 years to 90 years old. | ACTRN1261300681752 |
| Biocurcumax from curry spice turmeric in retaining cognitive function | N/A | Australia | Psychometric testing using Mini-Mental State Examination (MMSE), CAMDEX-R and (CAMCOG)-R, etc. | Oral 500 mg three times daily (total 1500 mg/day). | Sample size: 134; Gender: all; Ages: 65 years to 90 years old. | ACTRN12611000437965 |
Table 3. Cont.

| Intervention          | Topic                                         | Phase | Trial Country     | Primary Endpoints                                                                 | Dose                      | Subjects                                      | Registration Number |
|-----------------------|-----------------------------------------------|-------|-------------------|-----------------------------------------------------------------------------------|---------------------------|-----------------------------------------------|--------------------|
| Curcumin (5)          | Efficacy and Safety of Curcumin Formulation in Alzheimer’s Disease | 2     | India             | To determine if curcumin formulation affects mental capacity in Alzheimer’s patients based on mental exams. | Oral 2000 mg or 3000 mg daily BID. | Sample size: 26; Gender: all; Ages: 50 years to 80 years old. | NCT01001637        |
| Curcumin (5)          | A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer’s Disease | 1/2   | Hong Kong, China  | Change in isoprostane level in plasma. Change in A-beta level in serum.          | Oral 1 g/4 g once daily. | Sample size: 36; Gender: all; Ages: 50 years and older. | NCT00164749        |
| Curcumin in Patients with Mild to Moderate Alzheimer’s Disease     | 2                                             | United States | Side effect checklist.                                                                | N/A                       | Sample size: 33; Gender: all; Ages: 50 years and older. | NCT00099710        |
Four Nrf2 agonists have entered clinical trials for the treatment of PD (Schemes 1 and 2 and Table 4).

Vitamin D3 (8, IC$_{50}$ is 2.1 µM [131]) (the ability of VD3 in C3H10T1/2 fibroblasts to down-regulate gli1mRNA expression in a dose-dependent manner) is an important regulator of bone metabolism and calcium and phosphorus balance. It is converted from 1α-hydroxylase to its active metabolite 1,25(OH)$_2$D and is currently in phase 4 clinical trials [132,133]. The 1-hydroxy group and the 10-position exomethylene group play important roles in maintaining the activity of the compound. Most research has focused on the modification of side chains and the A ring [134]. Compound (2) can cross the blood–brain barrier. The treatment with 0.1% glucoraphanin pellets preserved dopaminergic neurons from neurodegeneration [135,136]. Currently, in phase 2 clinical trials, Compound (1) (20 µmol/L) acts by upregulating antioxidase activity [137], and it can effectively scavenge H$_2$O$_2$ [138]. EGCG is currently in phase 2 clinical trials for the treatment of PD. Monoamine oxidase (MAO) regulates the local levels of neurotransmitters such as dopamine, norepinephrine and serotonin, and (3) has a selective inhibitory effect on MAO-A [139]. Compound (3) is currently in phase 1 clinical trials.
Table 4. Four Nrf2 agonists used in some clinical trials for PD.

| Intervention                                                                 | Phase | Trial Country | Primary Endpoints                                                                                                                                                                                                 | Dose                              | Subjects                                      | Registration Number  |
|------------------------------------------------------------------------------|-------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------------------|---------------------|
| The Effects of Vitamin D and Bone Loss in Parkinson’s Disease                | 2     | United States | Direct changes in bone formation and resorption will be investigated by measuring serum 25-hydroxyvitamin D [25(OH)D] level, serum parathyroid hormone (PTH) levels, serum osteocalcin, and serum n-telopeptides (N-Tx). Time frame: 12 months. | 1000 IU/day of vitamin D3.         | Sample size: 23; Gender: all; Ages: 18 years and older. | NCT00907972          |
| Clinical Effects of Vitamin D Repletion in Patients With Parkinson’s Disease | 4     | United State  | Change from baseline visit to 3 months (treatment visit #1) in the TUG, timed walking task (8 m) and UPDRS III subscore. Time frame: 6 months.                                                             | 600 IU vitamin D capsule daily.    | Sample size: 31; Gender: All; Ages: 18 years to 89 years. | NCT00571285          |
| Vitamin D3 (8)                                                               | Not Applicable | Poland | The effects of vitamin D supplementation and physical activity on concentration of vitamin D3 in serum—the evaluation of changes before and after 12 weeks of supplementation and physical activity. Time frame: the outcome will be assessed up to 1 year after the last collection of blood. | Dosage based on the BMI as followed: for BMI under 25—4000 IU/day, for BMI between 25 and 30—5000 IU/day, and for BMI over 30—6000 IU/day. | Sample size: 72; Gender: all; Ages: 40 years to 90 years. | NCT04768023          |
| 12 Weeks Vitamin D Supplementation and Physical Activity in PD Patients With DBS | 2     | United States | Change in static balance as recorded using dynamic posturography with the sensory organization test (SOT 1–3).                                                                                                   | Drug: vitamin D3 at 10,000 IU a day. Dietary supplement: calcium 1000 mg calcium daily. | Sample size: 101; Gender: all; Ages: 50 years to 99 years. | NCT01119131          |
| Effects of Vitamin D in Parkinson’s Disease (PD)                            | 2     | United States |                                                                                                                                                                                                             |                                    |                                               |                     |
Table 4. Cont.

| Intervention                                                                 | Topic                                                                 | Phase | Trial Country | Primary Endpoints                                                                                                                                                                                                 | Dose                                                                                               | Subjects                                                                 | Registration Number   |
|------------------------------------------------------------------------------|----------------------------------------------------------------------|-------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------|
| Resveratrol (3)                                                              |                                                                      | 1     | Portugal      | 1. Maximum observed plasma drug concentration (Cmax) post-dose—levodopa. Time of occurrence of Cmax (tmax)—levodopa; 2. Area under the plasma concentration–time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t), calculated by the linear trapezoidal rule—levodopa; 3. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞), calculated from AUC0-t + (Clast/λz), where Clast is the last quantifiable concentration and λz is the apparent terminal rate constant—levodopa; 4. Apparent terminal half-life; calculated from ln 2/λz (t1/2)—levodopa; 5. Maximum observed plasma drug concentration (Cmax) post-dose—BIA 6-512; 6. Time of occurrence of Cmax (tmax)—BIA 6-512; 7. Area under the plasma concentration–time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t), calculated by the linear trapezoidal rule—BIA 6-512; 8. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞), calculated from AUC0-t + (Clast/λz), where Clast is the last quantifiable concentration and λz the apparent terminal rate constant—BIA 6-512; 9. Apparent terminal half-life calculated from ln 2/λz (t1/2)—BIA 6-512. | One capsule of Madopar® HBS 125 (levodopa 100 mg/benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo. | Sample size: 20; Gender: all; Ages: 18 years to 45 years. | NCT03091543           |
Table 4. Cont.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| Resveratrol (3) | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | 1 | Portugal | 1. Day 4—Maximum observed plasma drug concentration (Cmax); 2. Day 4—Time of occurrence of Cmax (tmax); 3. Day 4—Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t); 4. Day 4—AUC from time zero to 8 h post-dose (AUC0-τ); 5. Day 4—Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞); 6. Day 4—Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2). 7; Day 5—Maximum observed plasma drug concentration (Cmax); 8. Day 5—Time of occurrence of Cmax (tmax); 9. Day 5—Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t); 10. Day 5—AUC from time zero to 8 h post-dose (AUC0-τ); 11. Day 5—Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞); 12. Day 5—Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2). | The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water. | Sample size: 38; Gender: all; Ages: 18 years to 45 years. | NCT03097211 |
| EGCG (1) | Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson’s Disease Patients | 2 | China | Delay of progression of motor dysfunction. | N/A | Sample size: 480; Gender: all; Ages: 30 years and older. | NCT00461942 |
| Sulforaphane (2) | A 6-month Study to Evaluate Sulforaphane Effects in PD Patients | 2 | China | Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score. | N/A | Sample size: 100; Gender: all; Ages: 40 years to 75 years. | NCT05084365 |
2.5. Nrf2 and Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic disease characterized by the loss of immune tolerance. SLE has a variety of clinical manifestations, the main sign of which is the production of autoantibodies that cause tissue damage [140]. Toll-like receptor 9 (TLR9) is an important bridge linking innate and adaptive immunity. For example, when the body is subjected to specific external stimuli, TLR9 activates the NF-κB pathway, leading to inflammation. T helper type 17 (Th17) cells are major proinflammatory T cells involved in the regulation of lupus nephritis (LN) through multiple mechanisms.

Signal transducer and activator of transcription 3 (STAT3) directly regulates interleukin-17 (IL-17) expression and suppresses cytokine signaling 3 (Socs3), which negatively regulates Th17 differentiation by downregulating STAT3 phosphorylation. Nrf2 inhibits Th17 differentiation and reduces STAT3 phosphorylation by upregulating Socs3 expression (Figure 6) [141]. SLE can affect bone metabolism and serum electrolysis through renal impairment and by disturbing endocrine homeostasis [142]. In general, dysimmunity, oxidative stress, and inflammation are the key pathogenic features of SLE and LN [143,144]. Preventing SLE development in humans might be facilitated by activating the Nrf2 pathway and applying other antioxidant therapies.

Figure 6. The mechanism of Nrf2 in SLE.

Three Nrf2 agonists have entered clinical research trials as a treatment for SLE (Schemes 1–3 and Table 5).
Table 5. Three Nrf2 agonists used in some clinical trials for SLE.

| Intervention                                                                 | Topic                                                                 | Phase | Trial Country       | Primary Endpoints                                                                                                                                                                                                 | Dose                                                                                                                                                                                                                           | Subjects                              | Registration Number       |
|------------------------------------------------------------------------------|----------------------------------------------------------------------|-------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------------|
| Curcumin (5)                                                                 | Effect of Curcumin on Systemic Lupus Erythematosus                    | 2     | California, United States | Change in SLEDAI.                                                                                                                                                                                                  | Intervention is 2 g of curcumin supplement per day.                                                                                                                                                                           | Sample size: 23; Gender: all; Ages: 18 years and older | NCT03953261 |
|                                                                              | Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients | 2     | Indonesia           | 1. Disease activity from the SLE patients after the Treatments; 2. Fatigue assessment from the SLE patients after the treatments; 3. Comparison of cytokine levels before and after the treatments. | The third group received 400 IU cholecalciferol (Nature Plus) t.i.d and curcumin (600 mg)—piperine (15,800 mg) (Bioglan) one time daily.                                                                                     | Sample size: 45; Gender: all; Ages: 18 years to 45 years | NCT05430087 |
| Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus               | 2                     | California       | Change in average IFN module expression level Percentage of Subjects by treatment arm experiencing any adverse event (AE) ≥ grade 3. | 6000 IU of vitamin D3 by mouth daily until the subject’s serum 25 (OH) level is ≥ 40 ng/mL, at which point the supplementation dose is reduced to 4000 IU/day. Note: Subjects weighing < 40 kg (kg) at study entry will receive their dose five days a week and all other subjects seven days a week. | 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight.                                                                                                                                           | Sample size: 7; Gender: all; Ages: 5 years to 20 years | NCT01709474 |
| Vitamin D3 in Systemic Lupus Erythematosus                                  | 2                     | United States    | Percent of s with an IFN alpha signature response at Week 12. | 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight.                                                                                                                                 | 5000 International units versus 400 international units as an active comparator.                                                                                                                                                 | Sample size: 57; Gender: all; Ages: 18 years and older | NCT00710021 |
| Vitamin D to Improve Endothelial Function in SLE                             | 2                     | United States    | Change at week 16 in % flow-mediated dilation in those who did and did not replete vitamin D. | 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight.                                                                                                                                | 5000 International units versus 400 international units as an active comparator.                                                                                                                                                 | Sample size: 9; Gender: all; Ages: 18 years and older | NCT01911169 |
| Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)       | 1                     | United States    | Hypercalcuria.                                                                                                                                         | Cholecalciferol 800 IU oral daily. Cholecalciferol 2000 IU oral daily. Cholecalciferol 4000 IU oral daily.                                                                                                                  | Cholecalciferol 800 IU oral daily. Cholecalciferol 2000 IU oral daily. Cholecalciferol 4000 IU oral daily.                                                                                                               | Sample size: 18; Gender: all; Ages: 18 years to 85 years | NCT00418587 |
Table 5. Cont.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|--------------------|
| Vitamin D3 (8) | Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients | 2 | Indonesia | 1. disease activity from the SLE patients after the treatments; 2. Fatigue assessment from the SLE patients after the treatments; 3. Comparison of cytokine levels before and after the treatment | The second group received a tablet containing curcumin (632 mg)—piperine (15,800 mg) (Bioglan) one time daily and a placebo (Saccharum lactis) t.i.d. | Sample size: 45; Gender: all; Ages:18 years to 45 years. | NCT05430087 |
| Vitamin D3 (8) | Effect of Vitamin D Supplement on Disease Activity in SLE | Not Applicable | Thailand | To examine the effect of vitamin D supplementation on SLE disease activity. | Add on vitamin D2 (calciferol) 40,000 IU/wk (2 cap) for 12 weeks. | Sample size: 100; Gender: all; Ages: 18 years and older. Sample size: 248; Gender: all; Ages: 30 years and older. | NCT05260255 |
| Vitamin D3 (8) | The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE) | Not Applicable | Egypt | Decrease in SLE disease activity. | 2000 IU/day for 12 months. | | NCT01425775 |
| SM934 (9) | Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | 2 | China | 1. Percentage of subjects with lupus low disease activity score (LLDAS) in each group; 2. Percentage of subjects with systemic lupus erythematosus responder index—4 (SRI-4) response in each group; 3. Percentage of subjects with treatment-emergent adverse events (TEAEs) in each group. | SM934 10 mg (5 tablet) p.o. qd in combination with steroids. | Sample size: 48; Gender: all; Ages: 30 years and older. | NCT03951259 |
Compound (5) can inhibit inflammatory pathways, neutralize free radicals, and inhibit ROS production [145,146]. It is currently in phase 2 clinical trials as an immunomodulator for the treatment of SLE. Clinical trials of (8) for the treatment of SLE are in phase 2.

β-Aminoarteether maleate (SM934) (9, IC_{50} is 1.24 µM [147]) (immunosuppression method of spleen cell proliferation induced by Con and LPS) is a water-soluble derivative of artemisinin. SM934 can inhibit TLR7/9 expression [148,149], renal antibody production, and the accumulation of inflammatory cytokines [150]. This compound has entered phase 2 clinical trials. The peroxy bridge of SM934 is the key group enabling its functionality. The aminoethyl group in the structure increases its water solubility, reduces toxicity and side effects, and enhances efficacy [151].

2.6. Nrf2 and Liver Injury

The liver is the largest digestive gland in the human body. It has basic functions such as secreting bile, breaking down sugars and storing glycogen, detoxification, phagocytosis, and defense. Oxidative stress caused by drugs, viruses, alcohol, and other factors is the main cause of liver damage, which can further aggravate drug-induced liver damage, fatty liver, viral hepatitis, autoimmune liver disease, liver fibrosis, and primary liver cancer. The Nrf2 pathway is widely involved in many aspects of the body’s defense against oxidative stress, such as detoxification, anti-inflammatory processes, and the regulation of cellular metabolism [152–156].

2.6.1. Role of Nrf2 in Nonalcoholic Fatty Liver Disease (NAFLD)

NAFLD is the most common chronic liver disease worldwide and is mainly characterized by a clinicopathological syndrome of excessive deposition of fat in liver cells. It can be caused by excessive alcohol intake and other liver-damaging factors. There are many structural and functional abnormalities in the mitochondria of NAFLD patients [157] that lead to the overproduction of ROS and cytokines. This triggers lipid peroxidation, and the generated ROS and lipid peroxidation products further damage mitochondrial function [158] in a vicious cycle (Figure 7). There is currently no definitive drug treatment for NAFLD.

![Figure 7. Pathogenesis of NAFLD.](image)

Three Nrf2 agonists have entered clinical research for the treatment of NAFLD (Scheme 1 and Table 6).
Table 6. Three Nrf2 agonists used in some clinical trials for NAFLD.

| Intervention                                                                 | Phase | Trial Country | Primary Endpoints                                                                                                                                                                                                 | Dose                                                                 | Subjects                          | Registration Number        |
|------------------------------------------------------------------------------|-------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------|---------------------------|
| Liraglutide Efficacy Study of Liraglutide vs. Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects | 4     | China         | To compare the change of intrahepatic lipids (IHL) in type 2 diabetic patients with nonalcoholic fatty liver disease after a 26-week treatment of liraglutide, sitagliptin, or insulin glargine per day combined with metformin. | Liraglutide, 0.6 mg per day for the first week, increased to 1.2 mg per day for the second week, and finally 1.8 mg per day from the third week. | Sample size: 75; Gender: all; Ages: 30 years to 75 years. | NCT02147925               |
| Liraglutide Antidiabetic Effects on Intrahepatic Fat                         | 4     | China         | Intrahepatic fat change from baseline by quantitative ultrasound.                                                                                                                                              | 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week. | Sample size: 87; Gender: all; Ages: 17 years to 80 years. | NCT03068065               |
| Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | 2     | England       | Liver histological improvement.                                                                                                                                                                              | 1.8 mg once daily, subcutaneous injection. 0.6–1.8 mg subcutaneous per day. | Sample size: 52; Gender: all; Ages: 18 years to 70 years. | NCT01237119               |
| Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | 2     | Canada        | Improvement in liver steatosis defined by change in liver fat fraction as measured by MRI and MR spectroscopy at baseline and 12 weeks of treatment.                                                           |                                                                                                                                  | Sample size: 35; Gender: all; Ages: 18 years and older. | NCT01399645               |
| Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease | N/A   | Denmark       | Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance. Time frame: six months. Changes from baseline after treatment with either resveratrol or placebo. Primary Side effect profile determined by interview and serum biochemistry. Side effect profile determined by serum biochemistry: AST, ALT, total and conjugated bilirubin, Creatinine, sodium, potassium, calcium, magnesium, chloride and TC02, haemoglobin, haematocrit, white blood cell and platelet counts, erythrocytes, and fasting lipid levels (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides). Fasting glucose and insulin levels. PT/INR and PTT levels. | 500 mg 3 times daily for six months. | Sample size: 26; Gender: all; Ages: 25 years to 65 years. | NCT01446276               |
| Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents | 2/3   | Canada        |                                                                                             | Oral 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days. | Sample size: 10; Gender: all; Ages: 13 years to 18 years. | NCT02216552               |
| Resveratrol (3)                                                              |       |               |                                                                                             |                                                                                                                                  |                                                                                               |                          |
| Resveratrol in Patients With Non-alcoholic Fatty Liver Disease               | 2/3   | Denmark       | Changes in hepatic and inflammatory markers ind the blood such as ALT, hs-CRP, TNFa; changes in hepatic fat content, assessed by MR spectroscopy; changes in hepatic steatosis and inflammation, assessed histologically; changes in the expression of proteins in the relevant inflammatory pathways, assessed by gene expression studies. | 500 mg 3 times daily for 6 months. | Sample size: 28; Gender: all; Ages: 18 years to 70 years. | NCT01464801               |
| Intervention (3) | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|-----------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| Resveratrol     | The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis | 2/3 | America | Alaninaminotransferase (ALT). | One resveratrol capsule per day for 12 weeks. | Sample size: 50; Gender: all; Ages: 18 years to 80 years. | NCT02030977 |
| Resveratrol     | Potential Beneficial Effects of Resveratrol | N/A | Denmark | Metabolic parameters. Time frame: five weeks. Regarding glucose, protein, and fat metabolism. | 500 mg three times a day for five weeks. | Sample size: 24; Gender: male; Ages: 18 years and older. | NCT01150955 |
| Curcumin (5)    | Curcumin for Pediatric Nonalcoholic Fatty Liver Disease | 2 | America | Change in serum alanine aminotransferase (ALT) from baseline. Time frame: 24 weeks. ALT value in U/L. | 500 mg daily phosphatidylcholine-curcumin complex supplement orally for 24 weeks. | Sample size: 0; Gender: all; Ages: 8 years to 17 years. | NCT04109742 |
| Curcumin (5)    | Curcumin Supplement in Nonalcoholic Fatty Liver Patients | 2/3 | America | Hepatic steatosis (time frame: 12 weeks) measured by CAP score using Fibroscan. | 1500 mg one capsule/day for 12 weeks. | Sample size: 50; Gender: all; Ages: 18 years and older. | NCT02908152 |
| Curcumin (5)    | The Effect of Curcumin on Liver Fat Content in Obese Subjects | N/A | Denmark | Curcumin’s effect on steatosis. Time frame: 42 days ± 3 days. Percentage of fat in the liver tissue measured by magnetic resonance spectroscopy. | 500 mg tablet (contains 100 mg curcumin); Dosage: 2 tablets twice daily for 42 days (± 3 days). | Sample size: 39; Gender: male; Ages: 20 years and older. | NCT03864783 |
| Curcumin (5)    | Efficacy of a Natural Components Mixture in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) | N/A | Italy | Hematocrit levels of hepatic enzymes AST, hematocrit levels of hepatic enzymes ALT, hematocrit levels of hepatic enzymes GGT. Time frame: before and at the end of treatment (three months). | Nutraceutical mixture (two soft 800 mg gelatin capsules per day) for three months. | Sample size: 126; Gender: male; Ages: 18 years to 80 years. | NCT02369536 |
Liraglutide increases the concentrations of Sestrin2 and Nrf2 and improves obesity-related NAFLD [159]. It is currently in phase 4 clinical trials. Resveratrol (3) was shown to attenuate methylation of the Nrf2 promoter in the liver of mice fed a high-fat diet (HFD) and attenuated NAFLD through epigenetic modification of Nrf2 signaling [160]. This compound is now in phase 2/3 clinical trials. Curcumin (5) treatment significantly alleviated liver steatosis in mice fed an HFD, reversed abnormal serum biochemical parameters, and increased the metabolic capacity to effectively restore the Nrf2-FXR-LXR pathway [161]. Curcumin is currently in phase 2/3 clinical trials.

In addition, a variety of natural Nrf2 activators such as aucubin [162], ginkgolide B [163], and limonin [164] can also alleviate NAFLD by regulating lipid metabolism and oxidative stress in hepatocytes. However, these compounds require further clinical investigation.

2.6.2. Role of Nrf2 in Viral Hepatitis

The core protein and nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) cause mitochondrial dysfunction in hepatocytes, and the resulting expression of cytochrome P450 2E1 (CYP2E1) and NADPH-oxidase (NOX) produces a large amount of ROS [165,166]. HCV core protein and NS5A can also activate Nrf2 to alleviate HCV [167], while HCV can cause MAF to translocate and bind to extranuclear nonstructural protein 3 (NS3), which then binds to Nrf2 in the cytoplasm, preventing Nrf2 from entering the nucleus [168–170]. The hepatitis B x protein (HBx) of hepatitis B virus (HBV) can alter a variety of mitochondria-related functions and is an important cause of mitochondrial dysfunction [171]. HBV can enhance the interaction between p62 and Keap1 to form the HBx-p62-Keap1 complex in the cytoplasm, thereby promoting Nrf2 expression [172] (Figure 8).

Currently, silymarin is the only Nrf2-related compound that has entered clinical trials for the treatment of HCV (Scheme 4 and Table 7). Silymarin (10, IC_{50} is 1.70 µM [173]) (measure metabolite concentrations with a fluorescence spectrometer at an excitation wavelength of 409 nm and an emission wavelength of 530 nm; the positive control runs on the same plate), refers to a class of flavonoid lignans extracted from the fruit and seeds of the Compositae herb, *Silybum marianum*; these lignans contain dihydroflavonols and phenylpropanoid derivatives [174]. Silymarin has entered phase 3 clinical trials [175]. Multiple phenolic hydroxyl and methoxy groups endow silymarin with good antioxidant activity. The introduction of methoxy groups on the B ring and the E ring improves the ability of silymarin to scavenge superoxide free radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals [176]. Esterification of the 3- or 23-hydroxyl of silymarin significantly improves its solubility, but its biological activity is reduced [177].

![Figure 8. Roles of Nrf2 in viral hepatitis.](image-url)
Table 7. Silymarin used in some clinical trials for HCV.

| Intervention | Topic | Phase | Trial Country | Primary Endpoints | Dose | Subjects | Registration Number |
|--------------|-------|-------|---------------|-------------------|------|----------|---------------------|
| Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C | 2 | Iran | The investigators measured serum amino transferases using commercial AST kits and ALT kits (Bayer Diagnostics, Tarrytown, NY, USA) at six months after silymarin admission. | 210 mg tabs; 630 mg daily for six months. | Sample size: 55; Gender: all; Ages: child, adult, older adult. | NCT01292161 |
| Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy | 3 | Korea | The proportion of patient with serum ALT less than or equal to 40 IU/L or achieves at least 50% decline to less than 60 IU/L. | 700 mg thrice daily. | Sample size: 53; Gender: all; Ages: 18 years and older. | NCT01258686 |
| Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment | 2 | America | 1. Efficacy—whether or not serum ALT (mg/dl) is less than or equal to 45 IU/L (approximate normal range) or achieves at least 50% decline to less than 65 IU/L (approximately 1.5 times the upper limit of normal); 2. Safety—occurrence of a dose-limiting toxicity. Time frame: 24-week treatment period. | 1. 700 mg dose (5 pills, three times daily) for 24-week treatment period. 2. 420 mg dose (5 pills, three times daily) for 24-week treatment period. | Sample size: 154; Gender: all; Ages: 18 years and older. | NCT00680342 |
| Evaluating Silymarin for Chronic Hepatitis C Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis | 2 | America | N/A | N/A | N/A | NCT00303030 |
| 2/3 | Egypt | 1. Incidence, severity, and duration of adverse events. Time frame: four weeks after enrollment. 2. Normalization of total (< 1.0 mg/dl) and direct bilirubin (< 0.3 mg/dl). Time frame: four weeks after enrollment. | 280 mg three times daily for four weeks. | Sample size: 199; Gender: all; Ages: 18 years and older. | NCT00755950 |
| Phase I Trial of Silymarin for Chronic Liver Diseases Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients | 1 | America | Adverse events. Time frame: 10 days. | 280 mg every 8 h. | Sample size: 56; Gender: all; Ages: 18 years and older. | NCT00389376 |
| 2 | Italy | To determine the effect of post-transplant treatment with Legalon SIL on HCV viral load 30 days after the beginning of treatment. | 20 mg/kg silybinin, administered daily as a 2-h infusion for 14 days. | Sample size: 20; Gender: all; Ages: 18 years to 70 years. | NCT01518933 |
2.6.3. Role of Nrf2 in Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is an organ-specific chronic and cholestatic autoimmune liver disease. Nrf2 protein concentrations are elevated in PBC patients, but Nrf2 gene expression is significantly decreased, and Keap1 and p62 protein concentrations are significantly increased [178,179]. Aberrant Nrf2/Keap1 system integrity may affect the self-defense mechanism against oxidative stress in PBC.

Currently, only one Nrf2-related compound has entered clinical trials for PBC (Scheme 5 and Table 8). Ursodeoxycholic acid (11, IC$_{50}$ is 30.82 µM [180]) (structure of primary and secondary bile acids as well as corresponding potency in differential scanning fluorimetry binding and cell rounding assays) is a bile acid compound [180]. It is the only drug approved by the US FDA for the treatment of PBC, and it is still the first-line drug for the treatment of PBC. It is currently in phase 4 clinical trials. The 3 and 7 phenolic hydroxyls endow ursodeoxycholic acid with antioxidant activity; this compound also enhances Nrf2 activation in hepatocytes of PBC patients and increases thioredoxin (TRX) and thioredoxin reductase 1 (TrxR1) proteins, thereby relieving PBC [181]. Ursodeoxycholic acid derivatives modified by glycine at position 24 have strong antioxidant effects and fewer toxic side effects than the parent compound [182,183]. The 24-position carboxylic acid is substituted by a heterocycle to obtain a ursodeoxycholic acid derivative that can selectively deliver NO to the liver, significantly increase the concentration of cyclic guanosine 3', 5'-monophosphate (cGMP) in the liver, and effectively inhibit various inflammatory factors, such as interleukin and tumor necrosis factor [184]. This derivative has a good therapeutic effect for the treatment of liver damage and the associated inflammation.
Table 8. Ursodeoxycholic Acid used in some clinical trials for PBC.

| Intervention                                      | Topic                                                                 | Phase | Country | Primary Endpoints                                                                 | Dose                        | Subjects                                      | Registration Number |
|---------------------------------------------------|----------------------------------------------------------------------|-------|---------|-----------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------|--------------------|
| Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease - PBC |                                                        | 3     | China   | Efficiency is defined as the proportion of patients whose ALP levels of serum decreased more than 25% compared to baseline at treatment for 24 weeks. | 250 mg/8 h orally for 24 weeks. | Sample size: 199; Gender: all; Ages: 18 years to 70 years. | NCT01829698        |
| Clinical Research of UCDA Reducing Medication Regimen in Stable PBC                           |                                                        | 4     | China   | Liver biochemical markers (AST and ALP in U/L, BIL in µmol/L) that restored to normal increase (bilirubin > 17 µmol/L, ALP > 3 ULM, AST > 2 ULN) again are considered to be PBC recurrence. The rate of recurrence will be described in percent. | 1. 250 mg orally twice a day; 2. 250 mg orally once a day; 3. 250 mg orally three times a day. | Sample size: 90; Gender: all; Ages: 18 years to 65 years. | NCT04650243        |
| Ursodeoxycholic Acid (11)                         |                                                        | 4     | China   | The percentage of patients in biochemical remission, defined as normalization of serum ALT and IgG levels after treatment, per treatment group. | 13–15 mg/kg/d.             | Sample size: 90; Gender: all; Ages: 18 years to 70 years. | NCT04617561        |
| Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II |                                                        | 4     | China   | Change of liver enzymes between baseline and the end of the treatment period with 250 mg Ursofalk capsules and the end of treatment period with 500 mg Ursofalk tablets. | 500 mg orally for 24 weeks. | Sample size: 65; Gender: all; Ages: 18 years and older. | NCT01510860        |
| Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis |                                                        | 4     | Germany |                                                                                   |                             | Sample size: 65; Gender: all; Ages: 18 years and older. |                    |
| Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine |                                                        | N/A   | America | Compare the liver enzyme parameters (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, and total bilirubin) in three different moments before the treatment, under the treatment, and at the end of treatment. | 300 mg 13–15 mg/kg day for 3 months. | Sample size: 30; Gender: all; Ages: 18 years and older. | NCT03489889        |
2.6.4. Role of Nrf2 in Liver Fibrosis

Globally, the number of people with liver fibrosis is expected to increase from 740 million in 2017 to 821 million in 2022. An important cause of liver fibrosis is the activation of hepatic stellate cells (HSC). Ruart et al. found that damage to sinusoidal endothelial cells during acute liver injury aggravates oxidative stress and activates stellate cells to promote liver fibrosis; furthermore, autophagy-impaired liver sinusoidal endothelial cells (LSEC) can cause ROS accumulation and elevated p62 levels, which activates the upregulation of Nrf2 and its target genes [185].

At present, only one Nrf2-related compound has entered clinical research for the treatment of hepatic fibrosis (Scheme 6 and Table 9). Candesartan (12, IC<sub>50</sub> is 3.59 µM [186]) (Immunofluorescence was conducted with mouse anti-OC43 N protein antibody and followed by Alexa Flour 488 and DAPI. The IC<sub>50</sub> was calculated using automated image analysis software), is an angiotensin II (Ang II) receptor antagonist. Recent studies have found that candesartan’s antihepatic fibrosis effect occurs partly through the activation of Nrf2 and its downstream target genes [187]. Candesartan is in phase 3 clinical trials. One study found that the substitution of 2-ethoxy increases its antioxidant activity, and the substitution of the carboxyl group at the 4-position of the benzene ring increases its water solubility and improves its pharmacokinetic properties.

![Candesartan](image)

**Scheme 6.** Structures of candesartan.

**Table 9.** Candesartan used in clinical trials for liver fibrosis.

| Intervention          | Topic                                      | Phase | Country | Primary Endpoints                          | Dose | Subjects                                      | Registration Number |
|-----------------------|--------------------------------------------|-------|---------|--------------------------------------------|------|----------------------------------------------|--------------------|
| Candesartan (12)      | Effect of Some Drugs on Liver Fibrosis     | 3     | Egypt   | Change in Fibroscan or APRI score.          | 8 mg/day for 6 months. | Sample size: 45; Gender: all; Ages: 20 years and older. | NCT03770936        |

In addition, sitagliptin [188,189], liraglutide [190], and mulberrin [191] can reduce aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in mouse serum and alleviate stellate cell activation and liver fibrosis. These compounds are currently being investigated.

3. Conclusions

In conclusion, 12 of small molecule compounds targeting Nrf2 have entered clinical research for the treatment of inflammation-related diseases. According to different sources, these compounds can be divided into natural products and repurposed drugs.

Compounds 1, 2, 3, 5, 7, 9 and 10 are the chemical constituents of natural plants or their structural modifications. Among them, EGCG (1) and sulforaphane (2) are in clinical trials for the treatment of COVID-19, Alzheimer’s disease, and Parkinson’s disease; resveratrol (3) is in clinical trials for the treatment of COVID-19, Alzheimer’s disease, Parkinson’s disease, and liver injury; curcumin (5) is in clinical trials for the treatment of COVID-19 and rheumatoid arthritis; oleanolic acid derivatives (7) are in clinical trials for the treatment of
COVID-19; artemisinin derivative SM934 (9) is in clinical trials for the treatment of lupus erythematosus. Silymarin (10) is in clinical trials for the treatment of viral hepatitis.

Compounds 4, 6, 8 and 12 are the repurposed drugs. Dimethyl fumarate (4) is used in the treatment of multiple sclerosis (MS) in the United States, Europe, and other countries. Now, it is in clinical trials for the treatment of COVID-19 and rheumatoid arthritis; the antidepressant drug fluoxetine (6) is in clinical trials for the treatment of COVID-19. Vitamin D3 (8) is in clinical trials for the treatment of Parkinson’s disease and lupus erythematosus; the bile acid ursodeoxycholic acid (11), a drug used for the treatment of gallstone diseases, is now used in clinical trials for the treatment of autoimmune liver disease. Candesartan (12), a lipid-lowering drug, is in the clinical research stage for liver fibrosis.

It should be noted that there is now some genuine structural information about the NRF-2/KEAP system from crystallographic studies carried out in China which identifies a nucleophilic addition of a thiol on the protein target to a Michael acceptor in the drug molecule [192]. Several of the compounds described in this review contain either Michael acceptors or other electrophilic groups to which a thiol would add. Furthermore, the possibility of blocking the NRF-2/KEAP interaction with small molecule drugs has been discussed in some detail by the Strathclyde group led by Harnett [193]. These research results of the specific interaction between the small molecule drugs and target proteins provide a valuable basis for the further design of new drugs targeting Nrf2.

Drugs with various structural types that target Nrf2 have achieved promising clinical experimental results, which confirms the good drug ability of these compounds that target Nrf2. The therapeutic areas involved are diverse, and clinical drugs are scarce, so the development of related new drugs is of great value and significance. However, on the whole, the total number of compounds entering clinical research in this field is small, the structural types are not sufficiently rich, and the IC50 values of these compounds that have entered the clinical stage are all several to tens of µM, and further improvement of the activity is needed. Therefore, with the help of computer-supported drug design methods that optimize the structural characteristics of target proteins and by focusing on natural product components and their structural modifications, the design and development of highly active and selective Nrf2 agonists will provide the possibility for the discovery of novel drug molecules in the future.

Author Contributions: Literature review, analysis, writing—review and editing, Z.Z., Y.H., Y.Z., and L.Z.; supervision, W.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Industry, Education and Research of Science and Technology Department of Henan Province of China (No. 15210700041) and the Key Technologies R & D Program of Henan Province of China (No. 222102310279). The APC was funded by (No. 15210700041).

Acknowledgments: We thank Katherine Thieltges for editing the English text of a draft of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ACE2 angiotensin-converting enzyme 2
AD Alzheimer’s disease
AIH autoimmune hepatitis
AILI APAP-induced liver injury
ALD alcoholic liver disease
ALT alanine aminotransferase
AMPK adenosine 5’-monophosphate (AMP)-activated protein kinase
Ang II angiotensin II
APAP acetaminophen
APP/PS1 amyloid precursor protein plus presenilin-1
ARE antioxidant response element
ASH alcoholic steatohepatitis
AST aspartate aminotransferase
ATP adenosine triphosphate
Aβ β-amyloid
BACE β-site amyloid-precursor-cleaving enzyme
BMDCs bone-marrow-derived dendritic cells
CAT catalase
cGMP cyclic guanosine 3′, 5′-monophosphate
CLA collagen-induced arthritis
CNS central nervous system
COVID-19 Coronavirus Disease 2019
COX-2 Cyclooxygenase-2
Cul3 CULLIN3
CYP 450 cytochrome P450
CYP2E1 cytochrome P450 2E1
DAPI 4′,6-diamidino-2-phenylindole
DFT density functional theory
DILI drug-induced liver injury
DMF Dimethyl fumarate
DPPH 2,2-diphenyl-1-picrylhydrazyl
dTHP-1 Human THP-1 cells differentiated to the macrophage phenotype
EC Epicatechin
ECG Epicatechin gallate
EGC Epigallocatechin
EGCG (-)-epigallocatechin-3-gallate
FDA Food and Drug Administration
GCL glutamate cysteine ligase
GSH-Px glutathione peroxidase
GST glutathione-S-transferases
IC50 half maximal inhibitory concentration
IDMF di-(methyl fumarate)
IFN-I interferons
IL-17 interleukin-17
IL-1β interleukin 1 beta
IL-6 interleukin 6
iNOS inducible nitric oxide synthase
GCLC catalytic subunit of glutamate–cysteine ligase
GCLM glutamate-cysteine ligase modifier subunit
GSH glutathione
GSK-3 glycogen synthase kinase 3
HAS hydroxy-α-sanshool
HBV hepatitis B
HBx hepatitis B x protein
HCC hepatocellular carcinoma
HCV hepatitis C
HFD high-fat diet
HMOX-1 heme-oxigenase-1
HO-1 heme-oxigenase-1
HSC hepatic stellate cell ICC intrahepatic cholangiocarcinoma
Keap1 Kelch-like ECH-associated protein 1
LN lupus nephritis
LPS Lipopolysaccharide
LSEC liver sinusoidal endothelial cell
MAF musculoaponeurotic fibrosarcoma
MAO Monoamine oxidase
MS multiple sclerosis
NAFLD non-alcoholic fatty liver disease
NAPQI N-acetyl-1,4-benzoquinone imine
NDCP nuclear dot protein 52
References

1. Xie, J.; Gorle, N.; Vandendriessche, C.; Van Imschoot, G.; Van Wonterghem, E.; Van Cauwenberge, C.; Parthoens, E.; Van Hamme, E.; Lippens, S.; Van Hoecke, L.; et al. Low-grade peripheral inflammation affects brain pathology in the App(NL-G-F) mouse model of Alzheimer’s disease. *Acta Neuropathol. Commun.* 2021, 9. [CrossRef]

2. La Vitola, P.; Balducci, C.; Baroni, M.; Artioli, L.; Santamaria, G.; Castiglioni, M.; Cerovic, M.; Colombo, L.; Cadinelli, L.; Pollegioni, L.; et al. Peripheral inflammation exacerbates alpha-synuclein toxicity and neuropathology in Parkinson’s models. *Neuropathol. Appl. Neurobiol.* 2021, 47, 43–60. [CrossRef] [PubMed]

3. Singh, R.P.; Hahn, B.H.; Bischoff, D.S. Identification and Contribution of Inflammation-Induced Novel MicroRNA in the Pathogenesis of Systemic Lupus Erythematosus. *Front. Immunol.* 2022, 13, 848149. [CrossRef]

4. Lanquetin, A.; Leclercq, S.; de Timary, P.; Segobin, S.; Naveau, M.; Coulbault, L.; Maccioni, P.; Lorrai, I.; Colombo, G.; Vivien, D.; et al. Role of inflammation in alcohol-related brain abnormalities: A translational study. *Brain Commun.* 2021, 3, fcab154. [CrossRef] [PubMed]

5. Del Valle, D.M.; Kim-Schulze, S.; Huang, H.-H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; Stock, A.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* 2020, 26, 1636–1643. [CrossRef]

6. Jiang, X.; Zhou, X.; Yu, X.; Chen, X.; Hu, X.; Lu, J.; Zhao, H.; Cao, Q.; Gu, Y.; Yang, Y.; et al. High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients. *Mod. Pathol.* 2022, 35, 929–937. [CrossRef] [PubMed]
7. Gessl, I.; Aletaha, D.; Mandl, P. Response to: ‘Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis’” by Dumoulin et al. Ann. Rheum. Dis. 2021. [CrossRef] [PubMed]

8. Kopacz, A.; Kloska, D.; Forman, H.J.; Jozkowicz, A.; Grochet-Przeczek, A. Beyond repression of Nrf2: An update on Keap1. Free Radic. Biol. Med. 2020, 157, 63–74. [CrossRef]

9. Gao, L.; Kumar, V.; Vellichirammal, N.N.; Park, S.-Y.; Rudebush, T.L.; Yu, L.; Son, W.-M.; Pekas, E.J.; Wafi, A.M.; Hong, J.; et al. Functional, proteomic and bioinformatic analyses of Nrf2-and Keap1-null skeletal muscle. J. Physiol. Lond. 2020, 598, 5427–5451. [CrossRef] [PubMed]

10. Wang, Y.; Yang, C.; Elsheikh, N.A.H.; Li, C.; Yang, F.; Wang, G.; Li, L. HO-1 reduces heat stress-induced apoptosis in bovine granulosa cells by suppressing oxidative stress. Aging 2019, 11, 5535–5547. [CrossRef] [PubMed]

11. Yang, Y.; Zheng, J.; Wang, M.; Zhang, J.; Tian, T.; Wang, Z.; Yuan, S.; Liu, L.; Zhu, P.; Gu, F.; et al. NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling. Cancer Sci. 2021, 112, 641–654. [CrossRef]

12. Mohar, I.; Bott, D.; White, C.C.; McConnachie, L.A.; Kavanagh, T.J. Glutamate cysteine ligase (GCL) transgenic and gene-targeted mice for controlling glutathione synthesis. Curr. Protoc. Toxicol. 2009, 39, 6.16.1–6.16.20. [CrossRef]

13. Ayna, A.; Khoosnav, L.; Temel, Y.; Ciftci, M. Antibiotics as Inhibitor of Glutathione S-transferase: Biological Evaluation and Application. J. Agric. Food Chem. 2020, 68, 11410–11430. [CrossRef] [PubMed]

14. Sakamoto, T.; Imai, H. Hydrogen peroxide produced by superoxide dismutase SOD-2 activates sperm in Caenorhabditis elegans. J. Biol. Chem. 2017, 292, 14804–14813. [CrossRef] [PubMed]

15. Kobayashi, S.; Ikeda, Y.; Shigeno, Y.; Konno, H.; Fujii, J. γ-GLUTAMYLcysteine synthetase and γ-glutamyl transferase as differential enzymatic sources of γ-glutamylcysteine in mice. Am. J. Physiol. 2020, 52, 555–566. [CrossRef]

16. Yuan, J.; Wang, Z.; Wang, B.; Mei, H.; Zhai, X.; Zhuang, Z.; Chen, M.; Zhang, Y. Non-specific Immunity Associated Gut Microbiome in Aristichthys nobilis under Different Rearing Strategies. Genes Dis. 2021, 12, 916. [CrossRef] [PubMed]

17. Bartolini, D.; Arato, I.; Mancuso, F.; Giustarini, D.; Bellucci, C.; Vacca, C.; Aglietti, M.C.; Stabile, A.M.; Rossi, R.; Cruciani, G.; et al. Melatonin modulates Nrf2 activity to protect porcine pre-pubertal Sertoli cells from the abnormal H₂O₂ generation and reductive stress effects of cadmium. J. Pineal Res. 2022, 73, e12806. [CrossRef] [PubMed]

18. Several authors are listed, but the full references are not provided. The text continues with more articles and references, but the snippet provided is not complete.
33. Jang, M.; Park, Y.-I.; Cha, Y.-E.; Park, R.; Namkoong, S.; Lee, J.I.; Park, J. Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro. *Evid. Based Complement. Altern. Med.* **2020**, *2020*, 5630838. [CrossRef]

34. Hurst, B.L.; Dickinson, D.; Hsu, S. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication). *Microbiol. Infect. Dis.* **2021**, *5*, 1–6. [CrossRef]

35. QuiZen, D.; Heyuan, J. Pharmacology and Application of Tea Pigment. *China Tea 1997*, **05**, 36–37.

36. Ali, M.; Bonay, M.; Vanhee, V.; Vinit, S.; Deramautd, T.B. Comparative effectiveness of 4 natural and chemical activators of Nrf2 on inflammation, oxidative stress, macrophage polarization, and bactericidal activity in an in vitro macrophage infection model. *PLoS ONE* **2020**, *15*, e0234484. [CrossRef]

37. Mohanty, S.; Sahoo, A.K.; Konkimalla, V.B.; Pal, A.; Si, S.C. Naringin in Combination with Isothiocyanates as Liposomal Formulations Potentiates the Anti-inflammatory Activity in Different Acute and Chronic Animal Models of Rheumatoid Arthritis. *ACS Omega* **2020**, *5*, 28319–28332. [CrossRef]

38. Sangeeta, M.; Abhisek, P.; Badireenath, K.V.; Sudam, C.S. Anti-Inflammatory and Anti-Granuloma Activity of Sulforaphane, a Bioactive Derivative of *Brassica* oleracea. *Evid. Based Complement. Altern. Med.* **2020**, *2020*, 10, 411–416. [CrossRef]

39. Ordonez, A.A.; Bullen, C.K.; Villabona-Rueda, A.F.; Thompson, E.A.; Turner, M.L.; Finotti, A.; Gambari, R. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. *Phytomedicine* **2021**, *87*, 153883. [CrossRef]

40. Zhu, L.; Wang, L.; Mou, X.; Zhao, F. Synthesis, Anti-inflammatory Activity and Molecular Docking of Resveratrol Amide Derivatives. *Bioorganic Med. Chem.* **2019**, *27*, 579–588. [CrossRef]

41. Hurst, B.L.; Dickinson, D.; Hsu, S. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication). *Microbiol. Infect. Dis.* **2021**, *5*, 1–6. [CrossRef]

42. Xin, M.; Wang, L.; Mou, X.; Zhao, F. Synthesis, Anti-inflammatory Activity and Molecular Docking of Resveratrol Amide Derivatives. *Bioorganic Med. Chem.* **2019**, *27*, 579–588. [CrossRef]

43. Jang, M.; Park, Y.-I.; Cha, Y.-E.; Park, R.; Namkoong, S.; Lee, J.I.; Park, J. Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro. *Evid. Based Complement. Altern. Med.* **2020**, *2020*, 5630838. [CrossRef]

44. Boehm, J.; Davis, R.; Murar, C.E.; Li, T.; McCleland, B.; Dong, S.; Yan, H.; Kerrs, J.; Moody, C.J.; Wilson, A.J.; et al. Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo. *Investig. Ophthalmol. Vis. Sci.* **2021**, *62*, 25. [CrossRef]
57. Muri, J.; Wolleb, H.; Broz, P.; Carreira, E.M.; Kopf, M. Electrophilic Nrf2 activators and itaconate inhibit inflammation at low dose and promote IL-1β production and inflammatory apoptosis at high dose. *Redox Biol.* 2020, 36, 101647. [CrossRef]  
58. Bormann, M.; Alt, M.; Schipper, L.; van de Sand, L.; Le-Trilling, V.T.K.; Rink, L.; Heinen, N.; Madel, R.J.; Otte, M.; Waensch, K.; et al. Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro. *Viruses* 2021, 13, 1914. [CrossRef]  
59. Marin-Palma, D.; Tabares-Guevara, J.H.; Zapata-Cardona, M.I.; Florez-alvarez, L.; Yepes, L.M.; Rugeles, M.T.; Zapata-Builes, W.; Hernandez, J.C.; Taborda, N.A. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. *Molecules* 2021, 26, 6900. [CrossRef]  
60. Venkateswarlu, S.; Ramachandra, M.S.; Subbaraju, G.V. Synthesis and biological evaluation of polyhydroxycurcinominoids. *Bioorg. Med. Chem.* 2005, 13, 6374–6380. [CrossRef]  
61. Lee, K.-H.; Aziz, F.H.A.; Syahida, A.; Abas, F.; Shaari, K.; Israf, D.A.; Lajis, N.H. Synthesis and biological evaluation of curcumin-like diapentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. *Eur. J. Med. Chem.* 2009, 44, 3195–3200. [CrossRef]  
62. Su, I.-J.; Chang, H.-Y.; Wang, H.-C.; Tsai, K.-J. A Curcumin Analog Exhibits Multiple Biologic Effects on the Pathogenesis of Alzheimer’s Disease and Improves Behavioral, Inflammation, and beta-Amyloid Accumulation in a Mouse Model. *Int. J. Mol. Sci.* 2020, 21, 5459. [CrossRef] [PubMed]  
63. Schloer, S.; Brunotte, L.; Mecate-Zambrano, A.; Zheng, S.; Tang, J.; Ludwig, S.; Rescher, U. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. *Br. J. Pharmacol.* 2021, 178, 2339–2350. [CrossRef] [PubMed]  
64. Yoon, S.-H.; Lee, E.; Cho, D.-Y.; Ko, H.M.; Baek, H.Y.; Choi, D.-K.; Kim, E.; Park, J.-Y. Synthesis of 4-(3-oxo-3-phenylpropyl)morpholin-4-ium chloride analogues and their inhibitory activities of nitric oxide production in lipopolysaccharide-induced BV2 cells. *Biol. Pharm. Bull.* 2011, 34, 538–544. [CrossRef]  
65. Venkateswarlu, S.; Ramachandra, M.S.; Subbaraju, G.V. Synthesis and biological evaluation of polyhydroxycurcinominoids. *Bioorg. Med. Chem.* 2005, 13, 6374–6380. [CrossRef] [PubMed]  
66. Dechaumes, A.; Nekoua, M.P.; Belouzard, S.; Sane, F.; Engelmann, I.; Dubuisson, J.; Alidjinou, E.K.; Hober, D. Fluoxetine Can Suppressing Oxidative Stress through the SERT/p38 MAPK/Nrf2 pathway in rats. *Mol. Med. Rep.* 2017, 15, 673–680. [CrossRef] [PubMed]  
67. Zimmniak, M.; Kirschner, L.; Hilpert, H.; Geiger, N.; Danov, O.; Oberwinkler, H.; Steinke, M.; Sewald, K.; Seibel, J.; Bodem, J. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. *Sci. Rep.* 2021, 11, 5890. [CrossRef] [PubMed]  
68. Dechaumes, A.; Nekoua, M.P.; Belouzard, S.; Sane, F.; Engelmann, I.; Dubuisson, J.; Alidjinou, E.K.; Hober, D. Fluoxetine Can Inhibit SARS-CoV-2 In Vitro. *Microorganisms* 2021, 9, 339. [CrossRef] [PubMed]  
69. Park, J.-Y.; Kim, S.-W.; Lee, J.-K.; Im, W.B.; Jin, B.K.; Yoon, S.-H. Simplified Heterocyclic Analogues of Fluoxetine Inhibit Inducible Nitric Oxide Production in Lipopolysaccharide-Induced BV2 Cells. *Bioll. Pharm. Bull.* 2011, 34, 538–544. [CrossRef]  
70. Zimmniak, M.; Kirschner, L.; Hilpert, H.; Geiger, N.; Danov, O.; Oberwinkler, H.; Steinke, M.; Sewald, K.; Seibel, J.; Bodem, J. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. *Sci. Rep.* 2021, 11, 5890. [CrossRef] [PubMed]  
71. Dechaumes, A.; Nekoua, M.P.; Belouzard, S.; Sane, F.; Engelmann, I.; Dubuisson, J.; Alidjinou, E.K.; Hober, D. Fluoxetine Can Inhibit SARS-CoV-2 In Vitro. *Microorganisms* 2021, 9, 339. [CrossRef] [PubMed]  
72. Sun, Q.; Ye, F.; Liang, H.; Liu, H.; Li, C.; Lu, R.; Huang, B.; Zhao, L.; Tan, W.; Lai, L. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduct. Target. Ther.* 2021, 6, 212. [CrossRef]  
73. Honda, T.; Rounds, B.V.; Bore, L.; Finlay, H.J.; Favaloero, F.G.; Suh, N.; Wang, Y.; Sporn, M.B.; Gribble, G.W. Synthetic Oleanane and Ursane Triterpenoids with Modified Rings A and C: A Series of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages. *J. Med. Chem.* 2000, 43, 4233–4246. [CrossRef]  
74. Turpaev, K.; Welsh, N. Aromatic malononitriles stimulate the resistance of insulin-producing beta-cells to oxidants and inflammatory cytokines. *Eur. J. Pharmacol.* 2021, 84, 79–80. [CrossRef]  
75. Zheng, S.; Santosh Laxmi, Y.R.; David, E.; Dinkova-Kostova, A.T.; Shiavoni, K.H.; Ren, Y.; Zheng, Y.; Trevino, L.; Bumesteo, R.; Ojima, I.; et al. Synthesis, Chemical Reactivity as Michael Acceptors, and Biological Potency of Monocyclic Cyanoenones, Novel and Highly Potent Anti-inflammatory and Cytotoxicative Agents. *J. Med. Chem.* 2012, 55, 4837–4846. [CrossRef]  
76. Fu, L.; Lin, Q.-x.; Onyango, E.O.; Liby, K.T.; Sporn, M.B.; Gribble, G.W. Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids. *Org. Biomol. Chem.* 2017, 15, 6001–6005. [CrossRef] [PubMed]  
77. Fu, L.; Gribble, G.W. Efficient and Scalable Synthesis of Bardoxolone Methyl (CDDO-methyl Ester). *Org. Lett.* 2013, 15, 1622–1625. [CrossRef] [PubMed]  
78. Bellucci, E.; Terzeni, R.; La Paglia, G.M.C.; Gentileschi, S.; Tripoli, A.; Tani, C.; Alunno, A. One year in review 2016: Pathogenesis of rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2016, 34, 793–801. [PubMed]  
79. Ito, H.; Moritoshi, F.; Hashimoto, M.; Tanaka, M.; Matsuda, S. Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. *Inflamm. Regen.* 2018, 38, 7. [CrossRef] [PubMed]  
80. Guo, Q.; Wang, Y.; Xu, D.; Nossett, J.; Pavlos Nathan, J.; Xu, J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. *Bone Res.* 2018, 6, 107–120. [CrossRef] [PubMed]  
81. Maria Quinonez-Flores, C.; Aidee Gonzalez-Chavez, S.; Del Rio Najera, D.; Pacheco-Tena, C. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. *BioMed Res. Int.* 2016, 2016, 6097417. [CrossRef]  
82. Chadha, S.; Behl, T.; Kumar, A.; Khullar, G.; Arora, S. Role of Nrf2 in rheumatoid arthritis. *Curr. Res. Transl. Med.* 2020, 68, 171–181. [CrossRef] [PubMed]  
83. Holmstrom, K.M.; Kostov, R.V.; Dinkova-Kostova, A.T. The multifaceted role of Nrf2 in mitochondrial function. *Curr. Opin. Toxicol.* 2016, 1, 80–91. [CrossRef] [PubMed]  
84. Narapureddy, B.; Dubey, D. Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: Efficacy, safety, patient experience and adherence. *Patient Prefer. Adherence* 2019, 13, 1655–1666. [CrossRef] [PubMed]
82. Nishioku, T.; Kawamoto, M.; Okizono, R.; Sakai, E.; Okamoto, K.; Tsukuba, T. Dimethyl fumarate prevents osteoclastogenesis by decreasing NFATc1 expression, inhibiting of erk and p38 MAPK phosphorylation, and suppressing of HMGB1 release. *Biochim. Biophys. Res. Commun.* 2020, 530, 455–461. [CrossRef]

83. Yamaguchi, Y.; Kanzaki, H.; Katsumata, Y.; Itohiya, K.; Fukaya, S.; Miyamoto, Y.; Narimiya, T.; Wada, S.; Nakamura, Y. Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation. *J. Cell. Mol. Med.* 2018, 22, 1138–1147. [CrossRef]

84. Lal, R.; Dhalival, J.; Dhalival, N.; Dharavath, R.N.; Chopra, K. Activation of the Nrf2/HO-1 signaling pathway by dimethyl fumarate ameliorates complete Freund’s adjuvant-induced arthritis in rats. *Eur. J. Pharmacol.* 2021, 899, 174044. [CrossRef] [PubMed]

85. Chen, J.; Zhu, G.; Sun, Y.; Wu, Y.; Wu, B.; Zheng, W.; Ma, X.; Zheng, Y. 7-deacetyl-gedunin suppresses proliferation of Human Hacat cells by regulating nuclear factor erythroid 2-related factor 2. *Bioengineered* 2021, 12, 9993–10006. [CrossRef]

86. Xi, X.; Feng, S. Neuroprotective Effect of EGCG on Alzheimer Model Rats and Expression of PPARgamma mRNA. *Front. Cell. Neurosci.* 2019, 12, 350–357. [CrossRef] [PubMed]

87. Liu, W.; Zhai, Y.; Heng, X.; Che, F.Y.; Chen, W.; Sun, D.; Zhai, G. Oral bioavailability of curcumin: Problems and advancements. *J. Drug Target.* 2016, 24, 694–702. [CrossRef]

88. Gong, X.; Jiang, L.; Li, W.; Liang, Q.; Li, Z. Curcumin induces apoptosis and autophagy inhuman renal cell carcinoma cells via Akt/mTOR suppression. *Bioengineered* 2021, 12, 5017–5027. [CrossRef] [PubMed]

89. Lal, R.; Dhalival, J.; Dhalival, N.; Dharavath, R.N.; Chopra, K. Activation of the Nrf2/HO-1 signaling pathway by dimethyl fumarate ameliorates complete Freund’s adjuvant-induced arthritis in rats. *Eur. J. Pharmacol.* 2021, 899, 174044. [CrossRef] [PubMed]

90. Xu, Z.; Shaan, W.; Zhao, Z.; Zhang, B.; Liu, C.; Cai, H. Curcumin alleviates rheumatoid arthritis progression through the phosphatidylinositol 3-kinase/protein kinase B pathway: An in vitro and in vivo study. *Bioengineered* 2022, 13, 12899–12911. [CrossRef] [PubMed]

91. Chacko, A.; Delbaza, A.; Walkden, H.; Basu, S.; Armitage, C.W.; Eindorf, T.; Trim, L.K.; Miller, E.; West, N.P.; St John, J.A.; et al. Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk. *Sci. Rep.* 2012, 2759. [CrossRef] [PubMed]

92. Zhao, Z.; Shaan, W.; Zhao, Z.; Zhang, B.; Liu, C.; Cai, H. Curcumin alleviates rheumatoid arthritis progression through the phosphatidylinositol 3-kinase/protein kinase B pathway: An in vitro and in vivo study. *Bioengineered* 2022, 13, 12899–12911. [CrossRef] [PubMed]

93. Jo, C.; Gundemir, S.; Pritchard, S.; Jin, Y.N.; Rahman, I.; Johnson, G.V. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. *Nat. Commun.* 2021, 5, 3496. [CrossRef] [PubMed]

94. Zhang, X.X.; Tian, Y.; Wang, Z.T.; Ma, Y.H.; Tan, L.; Yu, J.-T. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. *J. Prev. Alzheimers Dis.* 2021, 8, 313–321. [CrossRef]

95. Bagherniya, M.; Darand, M.; Askari, G.; Guest, P.C.; Sathyapalan, T.; Sahebkar, A. The Clinical Use of Curcumin for the Treatment of Rheumatoid Arthritis. *J. Drug Target.* 2019, 27, 12516–12523. [CrossRef] [PubMed]

96. El Khoury, A.; Seidler, P.M.; Eisenberg, D.S.; Harran, P.G. Catalytic Synthesis of PEGylated EGCG Conjugates that Disaggregate Alzheimer’s Tau. *Synthesis* 2021, 53, 4263–4271. [CrossRef]

97. Rojo, A.I.; Pajares, M.; Rada, P.; Nunez, A.; Nevado-Holgado, A.J.; Killik, R.; Van Leuven, F.; Ribe, E.; Lovestone, S.; Yamamoto, M.; et al. Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk. *Sci. Rep.* 2012, 2759. [CrossRef] [PubMed]

98. Bahn, G.; Park, J.S.; Yun, U.J.; Lee, Y.J.; Choi, Y.; Park, J.S.; Baek, S.H.; Choi, B.Y.; Cho, Y.S.; Kim, H.K.; et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. *Proc. Natl. Acad. Sci. USA* 2019, 116, 12516–12523. [CrossRef]

99. Zhang, X.X.; Tian, Y.; Wang, Z.T.; Ma, Y.H.; Tan, L.; Yu, J.-T. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. *J. Prev. Alzheimers Dis.* 2021, 8, 313–321. [CrossRef]

100. Bahn, G.; Park, J.S.; Yun, U.J.; Lee, Y.J.; Choi, Y.; Park, J.S.; Baek, S.H.; Choi, B.Y.; Cho, Y.S.; Kim, H.K.; et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. *Proc. Natl. Acad. Sci. USA* 2019, 116, 12516–12523. [CrossRef]

101. Jo, C.; Gundemir, S.; Pritchard, S.; Jin, Y.N.; Rahman, I.; Johnson, G.V. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. *Nat. Commun.* 2021, 5, 3496. [CrossRef] [PubMed]

102. Xi, X.; Feng, S. Neuroprotective Effect of EGCg on Alzheimer Model Rats and Expression of PPARgamma mRNA. *Nat. Prod. Res. Dev.* 2016, 28, 596–600. [CrossRef] [PubMed]

103. Cao, A.; Ettcheto, M.; Chang, J.-H.; Barroso, E.; Espina, M.; Kühne, B.A.; Barenys, M.; Auladell, C.; Folch, J.; Souto, E.B.; et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficency of EGCG in a APPsw/PS1dE9 Alzheimer’s disease mice model. *J. Control. Release* 2019, 301, 62–75. [CrossRef] [PubMed]

104. El Khoury, A.; Seidler, P.M.; Eisenberg, D.S.; Harran, P.G. Catalytic Synthesis of PEGylated EGCG Conjugates that Disaggregate Alzheimer’s Tau. *Synthesis* 2021, 53, 4263–4271. [CrossRef] [PubMed]
105. Guo, Y.; Zhao, Y.; Nan, Y.; Wang, X.; Chen, Y.; Wang, S. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer’s disease. *Neuroreport* 2017, 28, 590–597. [CrossRef]

106. Lopez del Amo, J.M.; Fink, U.; Dasari, M.; Grello, G.; Wanker, E.E.; Bieschke, J.; Reif, B. Structural Properties of EGCG-Induced, Nontoxic Alzheimer’s Disease Aβ Oligomers. *J. Mol. Biol.* 2012, 421, 517–524. [CrossRef] [PubMed]

107. Hyung, S.J.; DeToma, A.S.; Brender, J.R.; Lee, S.; Vivekanandan, S.; Kochi, A.; Choi, J.S.; Ramamoorthy, A.; Ruotolo, B.T.; Lim, M.H. Insights into anti-amyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. *Proc. Natl. Acad. Sci. USA* 2013, 110, 3743–3748. [CrossRef]

108. Kim, H.J.; Jang, B.K.; Park, J.-H.; Choi, J.W.; Park, S.J.; Byeon, S.R.; Pae, A.N.; Lee, Y.S.; Cheong, E.; Park, K.D. A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model. *Eur. J. Med. Chem.* 2020, 185, 117777. [CrossRef]

109. Zhang, R.; Zhang, J.; Fang, L.; Li, X.; Zhao, Y.; Shi, W.; An, L. Neuroprotective Effects of Sulfuraphane on Cholinergic Neurons in Mice with Alzheimer’s Disease-Like Lesions. *Int. J. Mol. Sci.* 2014, 15, 14396–14410. [CrossRef]

110. Zhang, J.; Zhang, R.; Zhan, Z.; Li, X.; Zhou, F.; Xing, A.; Jiang, C.; Chen, Y.; An, L. Beneficial Effects of Sulfuraphane Treatment in Alzheimer’s Disease May Be Mediated through Reduced HDAC1/3 and Increased p75NTR Expression. *Front. Aging Neurosci.* 2017, 9, 121. [CrossRef]

111. Lee, S.; Choi, B.-R.; Kim, J.; LaFerla, F.M.; Han, J.-S.; Lee, K.W.; Kim, J. Sulfuraphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-beta and Tau in a Mouse Model of Alzheimer’s Disease. *Mol. Nutr. Food Res.* 2018, 62, e1800240. [CrossRef]

112. Zhao, H.; Wang, Q.; Cheng, X.; Li, X.; Li, N.; Liu, T.; Li, J.; Yang, Q.; Dong, R.; Zhang, Y.; et al. Inhibitive Effect of Resveratrol on the Inflammation in Cultured Astrocytes and Microglia Induced by Aβ1–42. *Neuroscience* 2018, 379, 390–404. [CrossRef] [PubMed]

113. Gu, J.; Li, Z.; Chen, H.; Xu, X.; Li, Y.; Gui, Y. Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial. *Neurol. Ther.* 2021, 10, 905–917. [CrossRef] [PubMed]

114. Alamro, A.A.; Alsalami, E.A.; Almutlaq, M.; Alghamedi, A.; Alokail, M.; Haq, S.H. Therapeutic Potential of Vitamin D and Curcumin in an In Vitro Model of Alzheimer Disease. *J. Cent. Nerv. Syst. Dis.* 2020, 12, 1179573520924311. [CrossRef] [PubMed]

115. Liu, Z.J.; Li, Z.H.; Liu, L.; Tang, W.X.; Wang, Y.; Dong, M.R.; Xiao, C. Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer’s Disease. *Front. Pharmacol.* 2017, 8, 261. [CrossRef]

116. Alizade, A.; Ozbolat, G. Antioxidant activities of inula viscosa extract and curcumin on U87 cells induced by beta-amyloid. *Cukurova Med. J.* 2021, 46, 583–588. [CrossRef]

117. Todorovic, M.; Ozbolat, G. Nrf2- Keap1 content in U87 cells induced by beta-amyloid. *Front. Mol. Neurosci.* 2018, 11, 36. [CrossRef] [PubMed]

118. Kasen, A.; Houck, C.; Burmeister, A.R.; Sha, Q.; Brundin, L.; Brundin, P. Upregulation of alpha-synuclein following immune activation: Possible trigger of Parkinson’s disease. *Neurobiol. Dis.* 2022, 166, 105654. [CrossRef]

119. Latif, S.; Jahangeer, M.; Makmoon Razia, D.; Aishiq, M.; Ghaffar, A.; Akram, M.; El Allam, A.; Bouyahya, A.; Garipova, L.; Ali Shariati, M.; et al. Dopamine in Parkinson’s disease. *Clin. Chim. Acta* 2021, 522, 114–126. [CrossRef]

120. Yi, G.; Din, J.U.; Zhao, F.; Liu, X. Effect of soybean peptides against hydrogen peroxide induced oxidative stress in HepG2 cells via Nrf2 signaling. *Food Funct.* 2020, 11, 2725–2737. [CrossRef]

121. Paraidathathu, T.; Degroot, H.; Kehrer, J.P. PRODUCTION OF REACTIVE OXYGEN BY MITOCHONDRIA FROM NORMOXIC AND HYPOXIC RAT-HEART TISSUE. *Free Radic. Biol. Med.* 1992, 13, 289–297. [CrossRef]

122. Wang, C.Y.; Zhang, Q.; Sun, Z.; Yuan, L.; Li, R.; Li, X.; Tian, S.Y.; Xin, N.; Xu, Y. Increases of iASPP-Keap1 interaction mediated by syringin enhance synaptic plasticity and rescue cognitive impairments via stabilizing Nrf2 in Alzheimer’s models. *Redox Biol.* 2020, 36, 101672. [CrossRef] [PubMed]

123. Nesi, G.; Sestito, S.; Digiacomo, M.; Rapposelli, S. Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer’s Disease. *Curr. Top. Med. Chem.* 2017, 17, 3062–3079. [CrossRef] [PubMed]

124. Guo, C.; Zhang, Y.; Nie, Q.; Cao, D.D.; Wang, X.X.; Wan, X.K.; Liu, M.; Cui, J.; Sun, J.; Bai, Y.F.; et al. SQSTM1/ p62 oligomerization contributes to AO-induced inhibition of Nrf2 signaling. *Neurobiol. Aging* 2021, 98, 10–20. [CrossRef]

125. Shah, S.Z.A.; Zhao, D.; Hussain, T.; Sabir, N.; Mangi, M.H.; Yang, L. p62-Keap1-NRF2-ARE Pathway: A Contentious Player for the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer’s disease. *Front. Mol. Neurosci.* 2018, 11, 310. [CrossRef] [PubMed]

126. Buhlman, L.M. Parkin loss-of-function pathology: Premature neuronal senescence induced by high levels of reactive oxygen species? *Mech. Ageing Dev.* 2017, 161, 112–120. [CrossRef] [PubMed]

127. Wang, C.Y.; Xu, Y.; Wang, X.; Guo, C.; Wang, T.; Wang, Z.Y. Di-3-n-Butylphthalide Inhibits NLRP3 Inflammasome and Mitigates Alzheimer’s-Like Pathology via Nrf2-TXNIP-Trx Axis. *Antioxid. Redox Signal.* 2019, 30, 1411–1431. [CrossRef]
130. Schepici, G.; Bramanti, P.; Mazzone, E. Efficacy of Sulforaphane in Neurodegenerative Diseases. *Int. J. Mol. Sci.* 2020, 21, 8637. [CrossRef]

131. DeBerardinis, A.M.; Banerjee, U.; Hadden, M.K. Identification of Vitamin D3-Based Hedgehog Pathway Inhibitors That Incorporate an Aromatic A-Ring Isostere. *ACS Med. Chem. Lett.* 2013, 4, 25–30. [CrossRef]

132. Salmon-Monte, T.C.; Torrente-Segarra, V.; Vega-Vidal, A.L.; Corzo, P.; Castro-Dominguez, F.; Ojeda, F.; Carbonell-Abelló, J. Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): A systematic review. *Autoimmun. Rev.* 2017, 16, 1155–1159. [CrossRef] [PubMed]

133. Tzilas, V.; Bouros, E.; Barbayianni, I.; Karampitsakos, T.; Kourtisidou, S.; Ntassiou, M.; Ninou, I.; Aidinis, V.; Bouros, D.; Tsouvelekis, A. Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. *Pulm. Pharmacol. Ther.* 2019, 55, 17–24. [CrossRef] [PubMed]

134. Choi, J.W.; Kim, S.; Yoo, J.S.; Kim, H.J.; Kim, H.J.; Kim, B.E.; Lee, E.H.; Lee, Y.S.; Park, J.H.; Park, K.D. Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson’s disease. *Eur. J. Med. Chem.* 2021, 212, 113103.

135. Hamijoyo, L.; Candrianita, S.; Rahmadi, A.R.; Dewi, S.; Darmawan, G.; Suryajaya, B.S.; Rainy, N.R.; Hidayat, I.I.; Moenardi, V.N.; Wachjudi, R.G. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: A cohort registry from an Indonesia-based tertiary referral hospital. *Lupus* 2019, 28, 1604–1609. [CrossRef]

136. Zhao, M.; Chen, H.; Ding, Q.; Xu, X.; Yu, B.; Huang, Z. Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/Ipr mice by Regulating Th17 Cell Function. *Sci. Rep.* 2016, 6, 38619. [CrossRef]

137. Ye, Q.; Wang, G.; Huang, Y.; Lu, J.; Zhao, J.; Zhu, L.; Zhu, Y.; Li, X.; Lan, J.; Li, Z.; et al. Mycophenolic Acid Exposure Optimization based on Vitamin D Status in Children with Systemic Lupus Erythematosus: A Single-Center Retrospective Study. *Rheumatol. Ther.* 2021, 8, 1143–1157. [CrossRef] [PubMed]

138. Doronicheva, N.; Yasui, H.; Sakurai, H. Chemical structure-dependent differential effects of flavonoids on the catalase activity as evaluated by a chemiluminescent method. *Biot. Pharm. Bull.* 2007, 30, 213–217. [CrossRef]

139. Zhang, Z.; Hamada, H.; Gerk, P.M. Selectivity of Dietary Phenolics for Inhibition of Human Monoamine Oxidases A and B. *BioMed Res. Int.* 2019, 2019, 861858. [CrossRef]

140. Hamijoyo, L.; Candrianita, S.; Rahmadi, A.R.; Dewi, S.; Darmawan, G.; Suryajaya, B.S.; Rainy, N.R.; Hidayat, I.I.; Moenardi, V.N.; Wachjudi, R.G. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: A cohort registry from an Indonesia-based tertiary referral hospital. *Lupus* 2019, 28, 1604–1609. [CrossRef]

141. Zhao, M.; Chen, H.; Ding, Q.; Xu, X.; Yu, B.; Huang, Z. Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/Ipr mice by Regulating Th17 Cell Function. *Sci. Rep.* 2016, 6, 38619. [CrossRef]

142. Ye, Q.; Wang, G.; Huang, Y.; Lu, J.; Zhao, J.; Zhu, L.; Zhu, Y.; Li, X.; Lan, J.; Li, Z.; et al. Mycophenolic Acid Exposure Optimization based on Vitamin D Status in Children with Systemic Lupus Erythematosus: A Single-Center Retrospective Study. *Rheumatol. Ther.* 2021, 8, 1143–1157. [CrossRef] [PubMed]

143. Kasai, S.; Shimizu, S.; Tataras, Y.; Mizuma, J.; Itoh, K. Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology. *Biomolecules* 2020, 10, 320. [CrossRef] [PubMed]

144. Ahmad, R.; Ahsan, H. Singlet oxygen species and systemic lupus erythematosus: A brief review. *J. Immunass. Immunochern.* 2019, 40, 343–349. [CrossRef] [PubMed]

145. Bai, Y.; Liu, Q.; Li, J.; Zhou, J. Protective mechanism of curcumin mediated HO-1 regulating Nrf2 signaling pathway on cadmium induced renal injury. *J. Toxicol.* 2020, 34, 291–295.

146. Singh, U.; Barik, A.; Singh, B.G.; Priyadarshini, K.I. Reactions of reactive oxygen species (ROS) with curcumin analogues: Structure-activity relationship. *Free Radic. Biol. Med.* 2011, 45, 317–325. [CrossRef]

147. Hou, L.E.; He, S.J.; Wang, J.X.; Yang, Y.; Zhu, F.H.; Zhou, Y.; He, P.L.; Zhang, Y.; Yang, Y.F.; Li, Y.; et al. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. *Int. Immunopharmacol.* 2009, 9, 1509–1517. [CrossRef]

148. Li, Y.; Zhao, L.; Yang, X.; Chen, J.; Xu, W.; Gu, Q. Artemisinin derivative SM934, influences the activation, proliferation, differentiation and antibody-secreting capacity of β-cells in systemic lupus erythematosus mice via inhibition of TLR7/9 signaling pathway. *Trop. J. Pharm. Res.* 2021, 18, 1391–1396. [CrossRef]

149. Deng, J.; Pan, J.; Li, H. Research progress of B cell-related targets in systemic lupus erythematosus. *Chin. J. Cell. Mol. Immunol.* 2016, 32, 1148–1150. [CrossRef]

150. Lin, Z.M.; Liu, Y.T.; Chen, L.; Cao, S.Q.; Huang, Y.T.; Yang, X.Q.; Zhu, F.H.; Tang, W.; He, S.J.; Zuo, J.P. Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets. *Sci. China-Life Sci.* 2021, 64, 1702–1719. [CrossRef]

151. Zheng, M.; Liu, G.; Tang, W.; Zuo, J.; Zhang, A.; Jiang, H. Structure-activity relationships of the antimarial agent artesiminin and the research progress on the artesiminin analogues with novel pharmacological actions. *Chin. Sci. Bull.* 2017, 62, 1948–1963. [CrossRef]

152. Yu, K.; Geng, X.; Chen, M.; Zhang, J.; Wang, B.; Ilic, K.; Tong, W. High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury. *Drug Metab. Dispos.* 2014, 42, 744–750. [CrossRef]

153. Lieber, C.S.; Rubin, E.; DeCarli, L.M. Hepatic microsomal ethanol oxidizing system (MEOS): Differentiation from alcohol dehydrogenase and NADPH oxidase. *Biochem. Biophys. Res. Commun.* 1970, 40, 858–865. [CrossRef]

154. Bailey, S.M.; Cunningham, C.C. Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. *Free Radic. Biol. Med.* 2002, 32, 11–16. [CrossRef]
155. Ishida, K.; Kaji, K.; Sato, S.; Ogawa, H.; Takagi, H.; Takaya, H.; Kawaratahi, H.; Moriya, K.; Namisaki, T.; Akahane, T.; et al. Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nr2f2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway. J. Nutr. Biochem. 2021, 89, 108573. [CrossRef] [PubMed]

156. Abd El-Hameed, N.M.; Abd El-Aleem, S.A.; Khattab, M.A.; Ali, A.H.; Mohammed, H.H. Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). Life Sci. 2021, 285, 119983. [CrossRef] [PubMed]

157. Sunny, N.E.; Bril, F.; Cusi, K. NAFLD Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends Endocrinol. Metab. 2017, 28, 250–260. [CrossRef] [PubMed]

158. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion 2006, 6, 1–28. [CrossRef] [PubMed]

159. Han, X.; Ding, C.H.; Zhang, G.D.; Liu, P.Y.; Huang, N.; Hou, N.N.; Han, F.; Xu, W.J.; Sun, X.D. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. Biochem. Biophys. Res. Commun. 2020, 525, 895–901. [CrossRef] [PubMed]

160. Hosseini, H.; Teimouri, M.; Shabani, M.; Koushki, M.; Khorzoughi, R.B.; Namvarjah, F.; Izadi, P.; Meshkani, R. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int. J. Biosch. Cell Biol. 2020, 119, 105667. [CrossRef] [PubMed]

161. Ishida, K.; Kaji, K.; Sato, S.; Ogawa, H.; Takagi, H.; Takaya, H.; Kawaratahi, H.; Moriya, K.; Namisaki, T.; Akahane, T.; et al. Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nr2f2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway. J. Nutr. Biochem. 2021, 89, 108573. [CrossRef] [PubMed]

162. Shen, B.; Zhao, C.; Wang, Y.; Peng, Y.; Cheng, J.; Li, Z.; Wu, L.; Jin, M.; Feng, H. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. J. Cell. Mol. Med. 2019, 23, 4063–4075. [CrossRef] [PubMed]

163. Yang, Y.; Chen, J.; Gao, Q.; Shan, X.; Wang, J.; Lv, Z. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology 2020, 445, 152599. [CrossRef] [PubMed]

164. Li, Y.; Yang, M.; Lin, H.; Yan, W.; Deng, G.; Ye, H.; Shi, H.; Wu, C.; Ma, G.; Xu, S.; et al. Limonin Alleviates Non-alcoholic Fatty Liver Disease by Reducing Lipid Accumulation, Suppressing Inflammation and Oxidative Stress. Front. Pharmacol. 2022, 12, 801730. [CrossRef] [PubMed]

165. Otani, K.; Korenaga, M.; Beard, M.R.; Li, K.; Qian, T.; Showalter, L.A.; Singh, A.K.; Wang, T.; Weinman, S.A. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005, 128, 96–107. [CrossRef] [PubMed]

166. Smirnova, O.A.; Ivanova, O.N.; Bartosch, B.; Valuev-Elliston, V.T.; Mukhtarov, E.; Kochetkov, S.N.; Ivanov, A.V. Hepatitis C Virus NS5A Protein Triggers Oxidative Stress by Inducing NADPH Oxidases 1 and 4 and Cytochrome P450 2E1. Oxidative Med. Cell. Longev. 2016, 201, 83419376. [CrossRef] [PubMed]

167. Ivanov, A.V.; Smirnova, O.A.; Petrushanko, I.Y.; Ivanova, O.N.; Karpenko, I.L.; Alekseeva, E.; Sominskaya, I.; Makarov, A.A.; Bartosch, B.; Kochetkov, S.N.; et al. HCV Core Protein Uses Multiple Mechanisms to Induce Oxidative Stress in Human Hepatoma Huh7 Cells. Viruses 2015, 7, 2745–2770. [CrossRef] [PubMed]

168. Carvajal-Yepes, M.; Himmelsbach, K.; Schaedler, S.; Ploen, D.; Krause, J.; Ludwig, L.; Weiss, T.; Klingel, K.; Hildt, E. Hepatitis C Virus Impairs the Induction of Cytoprotective Nrf2 Target Genes by Delocalization of Small Maf Proteins. J. Biol. Chem. 2011, 286, 8941–8951. [CrossRef] [PubMed]

169. Yu, J.-S.; Chen, W.-C.; Tseng, C.-K.; Lin, C.-K.; Hsu, Y.-C.; Chen, Y.-H.; Lee, J.-C. Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway. PLoS ONE 2016, 11, e0152236. [CrossRef]

170. Shen, J.; Wang, G.; Zuo, J. Caffeic acid inhibits HCV replication via induction of IFNalpha antiviral response through p62-mediated Keap1/Nrf2 signaling pathway. Antivir. Res. 2018, 154, 166–173. [CrossRef] [PubMed]

171. Mansourhi, A.; Gattolliat, C.-H.; Asselah, T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology 2018, 153, 629–647. [CrossRef] [PubMed]

172. Liu, B.; Fang, M.; He, Z.; Cui, D.; Jia, S.; Lin, X.; Xu, X.; Zhou, T.; Liu, W. Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation. Cell Death Dis. 2015, 6, e1980. [CrossRef] [PubMed]

173. Lee, C.K.; Choi, J.S. Effects of Silibinin, Inhibitor of CYP3A4 and P-Glycoprotein in vitro, on the Pharmacokinetics of Paclitaxel after Oral and Intravenous Administration in Rats. Pharmacology 2010, 85, 350–356. [CrossRef] [PubMed]

174. Kim, J.Y.; Kim, J.Y.; Jenis, J.; Li, Z.P.; Ban, Y.J.; Baiseitova, A.; Park, K.I. Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle). Bioorg. Med. Chem. 2019, 27, 2499–2507. [CrossRef] [PubMed]

175. Ahmed, S.; Ullah, N.; Parveen, S.; Javed, I.; Jalil, N.A.C.; Murtey, M.D.; Sheikh, I.S.; Khan, S.; Ojha, S.C.; Chen, K. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Med. Cell. Longev. 2022, 2022, 91999190. [CrossRef] [PubMed]

176. Gong, J.X.; Weng, L.J.; Wang, F.; Bin Feng, Y.; Zhou, C.X.; Li, H.B.; Wu, Y.H.; Hao, X.J.; Wu, X.M.; Bai, H.; et al. Synthesis and antioxidant properties of novel silybin analogues. Chin. Chem. Lett. 2006, 17, 465–468.

177. Kang, H.; Zheng, L.; Li, Z. Preparation and quality inspection of sodium 11- phosphodervative of silymarin. Chin. J. Pharm. 2004, 35, 71–72.
178. Wasik, U.; Milkiewicz, M.; Kempinska-Podhorodecka, A.; Milkiewicz, P. Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis. *Sci. Rep.* 2017, 7, srep44769. [CrossRef] [PubMed]

179. Czaja, A.J. Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis. *Curr. Pharm. Des.* 2011, 17, 3120–3140. [CrossRef] [PubMed]

180. Tam, J.; Ich, S.; Utama, E.; Orrell, K.E.; Gomez-Biagi, R.F.; Theriot, C.M.; Kroh, H.K.; Rutherford, S.A.; Lacy, D.B.; Mehryk, R.A. Intestinal bile acids directly modulate the structure and function of C. difficile TcdB toxin. *Proc. Natl. Acad. Sci. USA* 2020, 117, 6792–6800. [CrossRef]

181. Kawata, K.; Kobayashi, Y.; Souda, K.; Kawamura, K.; Sumiyoshi, S.; Takahashi, Y.; Noritake, H.; Watanabe, S.; Suehiro, T.; Nakamura, H. Enhanced Hepatic Nrf2 Activation After Ursodeoxycholic Acid Treatment in Patients with Primary Biliary Cirrhosis. *Antioxid. Redox Signal.* 2010, 13, 259–268. [CrossRef] [PubMed]

182. Brossard, D.; Lechevrel, M.; El Kihel, L.; Quesnelle, C.; Khalid, M.; Moslemi, S.; Reimund, J.-M. Synthesis and biological evaluation of bile carboxamide derivatives with pro-apoptotic effect on human colon adenocarcinoma cell lines. *Eur. J. Med. Chem.* 2014, 86, 279–290. [CrossRef]

183. Silva, S.L.; Vaz, A.R.; Diogenes, M.J.; van Rooijen, N.; Sebastiao, A.M.; Fernandes, A.; Silva, R.F.M.; Brites, D. Neuritic growth impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and prevented by glycoursodeoxycholic acid and interleukin-10. *Neuropsychopharmacology* 2012, 62, 2398–2408. [CrossRef] [PubMed]

184. Fiorucci, S.; Mencarelli, A.; Palazzetti, B.; Del Soldato, P.; Morelli, A.; Ignarro, L.J. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. *Proc. Natl. Acad. Sci. USA* 2001, 98, 2652–2657. [CrossRef]

185. Ruart, M.; Chavarria, L.; Camprecios, G.; Suarez-Herrera, N.; Montironi, C.; Guixe-Muntet, S.; Bosch, J.; Friedman, S.L.; Carlos Garcia-Pagan, J.; Hernandez-Gea, V. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. *J. Hepatol.* 2019, 70, 458–469. [CrossRef] [PubMed]

186. Xiao, X.; Wang, C.H.; Chang, D.; Wang, Y.; Dong, X.J.; Jiao, T.; Zhao, Z.D.; Ren, L.L.; Dela Cruz, C.S.; Sharma, L.; et al. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. *Front. Immunol.* 2020, 11, 586572. [CrossRef] [PubMed]

187. Kamel, E.O.; Gad-Elrab, W.M.; Ahmed, M.A.; Mohammedsaleh, Z.M.; Hassanein, E.H.M.; Ali, E.M. Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-kappa B, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. *Biol. Trace Elem. Res.* 2022, 1–18. [CrossRef]

188. Sharawy, M.H.; El-Kashef, D.H.; Shaaban, A.A.; El-Agamy, D.S. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-kappa B inhibition. *Int. Immunopharmacol.* 2021, 100, 108888. [CrossRef]

189. Abo-Haded, H.M.; Elkahlawy, M.A.; Al-Johani, Z.; Al-ahmadi, O.; El-Agamy, D.S. Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. *PLoS ONE* 2017, 12, e0174295. [CrossRef]

190. Ge, C.; Tan, J.; Lou, D.; Zhu, L.; Zhong, Z.; Dai, X.; Sun, Y.; Kuang, Q.; Zhao, J.; Wang, L.; et al. Mulberrin confers protection against hepatic fibrosis by Trimp31/Nrf2 signaling. *Redox Biol.* 2022, 51, 102274. [CrossRef] [PubMed]

191. Wu, G.; Zou, L.; Yuan, X.; Chen, H.; Xiong, R.; Zhang, S.; Cheng, H.; Shen, Y.; An, H.; Li, T.; et al. Britain Ameliorates Cerebral Ischemia-Reperfusion Injury by Inducing the Nrf2 Protective Pathway. *Antioxid. Redox Signal.* 2017, 27, 754–768. [CrossRef] [PubMed]

192. Rzepecka, J.; Pineda, M.A.; Al-Riyami, L.; Rodgers, D.T.; Huggan, J.K.; Lumb, F.E.; Khalaf, A.I.; Meakin, P.J.; Corbet, M.; Ashford, M.L.; et al. Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflamasome. *J. Autoimmun.* 2015, 60, 59–73. [CrossRef] [PubMed]